 
 
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory 
Advanced Biliary Cancers  
 
[STUDY_ID_REMOVED]  
 
Version 2.0 
April 5, 2017  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  1 of 59 
 
Title page 
 
Multi institutional phase II trial of single agent r egorafenib in refractory advanced biliary 
cancers.  
 
 
 
     
Test drug (s): Regorafenib 
[Study purpose:]  Efficacy 
Clinical study phase:  II 
Version no.:  2.0 Date:  01/27/2015     
Amendment no.:  4.0 Date:  04/05/2017     
Institution Study no.:  YYYYY 
Principal Investigator : Richard Kim M.D. Assistant Professor H. Lee Moffitt Cancer Center 
12902 Magnolia Drive FOB- 2 Tampa, FL 33647 
 Participating Institutions :       
                                             Hanna Sanoff M.D 
                                            University of North Carolina 
                                            Chapel Hill, NC 
                                             
                                             Andrew Poklepovic  M.D 
                                            
VCU Massey Cancer Center  
                                            Richmond, VA 
                                             
                                             Andrew Nixon PhD 
                                            Duke University  
                                            Durham, NC  
Research Nurse:  TBD  
Data Manager:  TBD 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  2 of 59 
 
Statistician:  Jongph il Kim PhD. Assistant Member, Department of Biostatistics, Moffitt Cancer 
Center & Research Institute tel:  813-745-6908 
The study will be conducted in compliance with the protocol, ICH -GCP and any applicable 
regulatory requirements.  
Confidential  
The information provided in this document is strictly confidential and is intended solely for the 
guidance of the clinical investigation.  Reproduction or disclosure of this document - whether in 
part or in full  - to parties not associated with the clinical investigation, or its use for any other 
purpose, without the prior written consent of the Principal Investigator  is not permitted.  
Throughout this document, symbols indicating proprietary names ( , TM) are not displayed.  
Hence, the appearance of product names without these symbols does not imply that these names 
are not protected.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  3 of 59 
 
Synopsis 
 
Title Multi institutional p hase II trial of single agent r egorafenib in 
refractory advanced biliary cancers .  
Clinical study phase  Phase II  
Study objective(s)  Primary Objective  
• To determine the 6 month overall  survival in patients with 
advanced refractory BC receiving r egorafenib. 
 
Secondary Objectives 
• To determine the frequency and severity of adverse 
events and tolerability of the regimen in patients with 
advanced refractory BC receiving r egorafenib  
• To evaluate the disease control rate (CR + PR+ SD) as 
defined by the RECIST 1.1 criteria in patients with 
advanced refractory biliary cancers (BC) receiving 
regorafenib at 8 weeks.  
• To determine the progression- free survival in patients 
with advanced refractory BC receiving r egorafenib  
Exploratory Objectives  
• To explore potentia l correlat ions betw een blood 
biomarke rs and cli nical outcome 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  4 of 59 
 
Background treatment  The outcome of patients with advanced biliary cancer remains 
dismal with the current standard of care options. There is 
currently an unmet medical need for patients with advanced BC 
who have failed one prior  systemic therapy . 
The second line setting therefore offers a unique opportunity to 
evaluate the activity of relevant molecularly targeted therapies 
and to identify potential predictive biomarkers. The fact that 
aberrant activation of the Ras/Raf/MAPK pathway occurs in 
more than 60% of BC indicates the importance of these 
pathways in biliary carcinogenesis and highlights potential new 
strategies in the treatment of this disease.  Further more anti -
angiogenic agents such as the VEGF- antagonist bevacizumab, 
and the multikinase inhibitor sorafenib have been tested in BC in 
the first line setting with modest  activity.  
Regorafenib is  an oral multi-kinase in hibitor that targe ts both 
recep tor tyrosine kinases (R TKs), as we ll as the tu mor cell 
proliferat ion/survival signa ling pa thway kinases 
(RAS/R AF/MEK/ERK ). In addition, regorafenib inhibits VEGFR-
2/3, TIE-2, c-KIT , and PDG FR-ß receptor phosphor ylation.  
Given the pivotal role of VEGF, the Ras/R af/MAPK pathway, and 
PDGFR- ß in biliary cancer biology, evaluation of the regorafenib  
in the second line setting represents a rational approach.  
Indication  Patients with advanced biliary tumor who have failed at least one 
prior line of systemic therapy.  
Diagnosis and main 
criteria for inclusion • Patients must have histologically or cytologically 
documented carcinoma primary to the intra- or extra-
hepatic biliary system or gall bladder with clinical and/or 
radiologic evidence of unresectable locally advanc ed or 
metastatic disease. Patients with ampullary carcinoma 
are not eligible.  
• Patients must have failed no mor e than 2 prior line of 
systemic chemotherapy for advanced biliary cancer. 
Patients who received adjuvant chemotherapy and had 
evidence of disease recurrence within 6 months of 
completion of the adjuvant treatment are also eligible. If 
patient received adjuvant treatment and had disease 
recurrence after 6 months, patients will only be eligible 
after failing one line of systemic chemotherapy used to 
treat the disease recurrence.  
 
• Patients must have measurable disease, as defined by 
RECIST 1.1 criteria.  
• Patients must not have been treated with any VEGF 
inhibitors.  
Study design  This is a multi -institutional phase II single  arm single -stage 
design trial  using regorafenib as a single agent.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  5 of 59 
 
Type of control  Patients will receive regorafenib 160 mg QD (21 days on and 7 
days off). After 2 cycles (1cycle= 28 days),  response and 
progression will be evaluated using the new international  criteria 
proposed by the revised Response Evaluation Criteria in Solid 
Tumors (RECIST)  guidelines (version 1.1) . 
Number of subjects  39 
Plan for statistical 
analysis Overall survival ( OS) will be defined as the time from starting on 
trial to date of death due to any cause. The final analysis will be 
conducted after the follow -time of the last patient exceeds 6 
months . OS  at 6 months  is the primary endpoint of the trial and 
will be estimated using the Kaplan- Meier method. The two-sided 
95% confidence interval (CI) for median OS w ill be computed 
using log -log transformation. The sample size was determined 
based on the Simon’s two- stage minimax design. With one- sided 
10% of type I error rate and 90% power, a sample of evaluable 
39 patients will be evaluated; 28 in first stage and ad ditional 11 
patients in second stage. If 8 or more out of 28 survive 6 months 
or more, the study goes on the second stage. The experimental 
treatment will be deemed to have good activity if ≥16 out of 39 
patients survive 6 months or more. 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  6 of 59 
 
Table of contents 
Title page .................................................................................................................................... 1 
Synopsis  ..................................................................................................................................... 3 
Table of contents  ........................................................................................................................ 6 
List of  abbreviations  .................................................................................................................... 8 
1. Introduction .......................................................................................................................... 9 
1.1 Background .................................................................................................................. 9 
1.2 Rationale of the study  ................................................................................................. 11 
1.3 Regorafenib ................................................................................................................ 11 
1.3.1 Preclinical ............................................................................................................ 12 
1.3.2 Clinical experience .............................................................................................. 12 
2. Study objectives  ................................................................................................................. 13 
3. Investigator[s] and other study participants  ........................................................................ 14 
4. Study design ...................................................................................................................... 14 
4.1 Eligibility  ..................................................................................................................... 14 
4.1.1 Inclusion criteria .................................................................................................. 14 
4.1.2 Exclusion criteria  ................................................................................................. 16 
4.1.3 Excluded therapies and medications, previous and conc omitant  ......................... 18 
4.2 Withdrawal of subjects from study  .............................................................................. 18 
4.2.1 Withdrawal  .......................................................................................................... 18 
4.2.2 Screen Failures/Dropouts  .................................................................................... 19 
4.2.3 Replacement  ....................................................................................................... 19 
5. Treatment[s]  ...................................................................................................................... 19 
5.1 Treatments to be administered ................................................................................... 19 
5.1.1 Regorafenib ........................................................................................................ 20 
5.1.2
 Dosage and administration:  ................................................................................. 20 
5.1.3 Study Treatment  .................................................................................................. 20 
5.1.4 Dose Modification for management of adverse events  ........................................ 20 
5.1.4.1 Dose Reduction Levels  ................................................................................ 20 
5.1.4.2 Prevention/management strategies for diarr hea .......................................... 30 
5.2 Drug logistics and accountability  ................................................................................. 30 
5.2.1 Accountability  ...................................................................................................... 30 
5.2.2 Destruction and Return ....................................................................................... 30 
5.3 Treatment compliance ................................................................................................ 31 
5.4 Prior and concomitant therapy  .................................................................................... 31 
6. Procedures and variables  .................................................................................................. 32 
6.1 Calendar  ..................................................................................................................... 32 
6.2 Safety  ......................................................................................................................... 34 
6.2.1 Advers e events  ................................................................................................... 34 
6.2.1.1 Definitions  .................................................................................................... 35 
6.2.1.2 Classifications for adverse event assessment  .............................................. 36 
6.2.1.2.1 Seriousness  .......................................................................................... 36 
6.2.1.2.2 Intensity  ................................................................................................ 36 
6.2.1.2.3 Causal relationship ............................................................................... 37 
6.2.1.2.4 Action taken with study treatment  ......................................................... 38 
6.2.1.2.5 Other specific treatment(s) of adverse events  ...................................... 38 
6.2.
1.2.6 Outcome ............................................................................................... 38 
7. CRITERIA FOR EVALUATION AND ENDPOINT ANALYSIS ............................................ 39 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  7 of 59 
 
7.1 Measurability of Lesions  ............................................................................................. 39 
7.2 Objective Status at Each Disease Evaluation ............................................................. 40 
7.3 Best Response ........................................................................................................... 42 
8. Statistical methods and determination of sample size ........................................................ 42 
8.1 Sample Size Determination ........................................................................................ 42 
8.2 Statistical Analysis  ...................................................................................................... 43 
9. Safety Monitoring  ............................................................................................................... 43 
9.1 Adverse events  ........................................................................................................... 44 
9.2 Serious adverse events  .............................................................................................. 45 
9.3 Reporting  of serious adverse events  ........................................................................... 45 
9.4 Adverse events of special safety interest  .................................................................... 46 
9.5 Pregnancies  ............................................................................................................... 46 
9.6 Further safety  ............................................................................................................. 47 
10. Premature termination of the study  .................................................................................... 47 
11. Data recording  ................................................................................................................... 47 
11.1 Institution al Review Board (IRB) App roval and Co nsent ............................................. 47 
11.2 Re quired Documen tation ............................................................................................  48 
11.3 Re gistration Procedures ............................................................................................. 49 
11.4 D ata Managemen t and Mon itoring/Auditing ................................................................ 49 
11.5 Ad
herence to the Pr otocol  .......................................................................................... 50 
11.6 Em ergency Modificat ions ............................................................................................  50 
11.7 R ecord Retenti on ........................................................................................................ 50 
11.8 Ob ligations of Investig ators ........................................................................................ 51 
12. Ethical and legal aspects  ................................................................................................... 51 
12.1 Ethical and legal conduct of the study  ........................................................................ 51 
12.2 Subject information and consent  ................................................................................ 52 
12.3 Publication policy  ........................................................................................................ 53 
12.4 Confidentiality  ............................................................................................................. 53 
13. Correlative studies  ............................................................................................................. 54 
13.1 Re quired Particip ation ................................................................................................ 54 
13.2 De tails on Potenti al Biomarker St udies b y Specimen ................................................. 54 
13.3 Special Instructions  .................................................................................................... 56 
13.4 Shipping  ..................................................................................................................... 56 
14. Reference list  ..................................................................................................................... 57 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  8 of 59 
 
List of abbreviations 
 
ADL Activities of Daily L iving  
ALT Alanine aminotransferase 
Ang Angiopoietin 
aPTT  Activated partial thromboplastin time 
AST Aspartate aminotransferase 
BID bis in die , twice  daily   
B-Raf B isoform of Rapidly Accelerated Fibrosarcoma protein 
BUN Blood Urea Nitrogen 
c-KIT Stem Cell Factor Receptor Tyrosine Kinase 
CR Complete Response 
C-RAF C isoform of Rapidly Accelerated Fibrosarcoma protein 
CTCAE  Common Terminology Criteria for Adverse Events  
DCE  Dynamic Contrast Enhanced 
ECOG  Eastern Cooperative Oncology Group 
EGFR Epidermal growth factor receptor  
ERK Extracellular Signal- regulated Kinases  
FDA Food and Drug Administration 
FGFR  Fibroblast Growth Factor R eceptor  
FLT3 FMS -like Tyrosine Kinase 3 
GCP  Good Cli nical Practice  
GMP  Good Manufacturing Practice 
HCC Hepatocellular Carcinoma 
HFSR Hand- foot-skin reaction 
IB Investigator’s Brochure 
IC50 Half M aximal  Inhibitory Concentration 
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IR Immediate R elease 
IRB Institutional Review Board 
MAPK Mitogen Activated Protein Kinase 
MEK  MAP Kinase / ERK Kinase 1  
NM Nano molar  
NYHA  New York Heart Association 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  9 of 59 
 
PD Progressive Disease 
PDGFR-β Platelet Derived Growth Factor Receptor -beta 
PFS Progression free survival  
PO per oris , oral  
PR Partial Response 
PS Performance Status  
PTT Partial thromboplastin time 
QD quaque die, once daily  
RAF Rapidly Accelerated Fibrosarcoma 
RAS Rat sarcoma 
RCC Renal Cell Carcinoma 
RECIST  Response Evaluation Criteria for Solid Tumors  
RET Rearranged during transfection 
RTK Receptor Tyrosine Kinase 
SAE Serious Adverse E vent 
SD Stable Disease 
SUSARs  Suspected Unexpected Serious Adverse Reactions  
TIE2  Tyrosine kinase with Immunoglobulin and Epidermal Growth Factor (EGF) 
homology domain 2 
TK Tyrosine K inase 
TTP Time to Progression 
VEGF  Vascular Endothelial Growth Factor  
VEGFR Vascular Endothelial Growth Factor Receptor  
 
1. Introduction 
1.1 Background 
Biliary cancer (BC) typically  includes intra and extrahepatic cholangiocarcinoma and 
cancers of the gallbladder.  In the United States, an estimated 2600 intrahepatic 
cholangiocarcinomas were diagnosed in 2010. [1],[2] In addition, about 10,000 cases of 
extrahepatic  bile duct cancer are diagnosed annually in the United States, two- thirds of 
which are gallbladder cancers. [1] Unfortunately, most patients have advanced disease at 
presentation and relapse despite surgery. [3] 
Data regarding chemotherapy have historically been disappointing in advanced BC, but 
new combinations show promise. ABC -02, a randomized phase III study recently 
published by Valle et al, enrolled more than 300 patients and compared gemcitabine plus cisplatin with gemcitabine alone. [4] The median overall survival (OS) and progression- free 
survival (PFS) were greater for gemcitabine plus cisplatin than for gemcitabine alone without significantly increased toxicity (OS: 11.7 v 8.2 months; log -rank P = .002; PFS: 8.5 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  10 of 59 
 
v 6.5 months;  P = .003). This drug combination set a new international standard of care 
for advanced biliary tract cancers. However, the survival for advanced BCs still rarely 
exceeds one year. This has led to a search for molecular targets for therapy. However, 
advances have been slow in part because of the tumor heterogeneity of BCs. [5] 
 
VEGF Pa thway 
The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) 
signaling pathway plays a pivotal role in tumor angiogenesis by promoting vascular and lymphatic endothelial cell proliferation, survival, and invasion, resulting in neovascularization, tumor growth, and metastasis. [6] 
VEGF has been found to be overexpressed in biliary tr act cancers and has thus been 
suggested as a potential prognostic marker and therapeutic target. [7, 8] VEGF express ion 
in biliary tract cancer has also been found to be an independent negative predictive 
marker. [9] Increased VEGF expression has been reported to be associated with 
significant vascularization of human intrahepatic cholangiocarcinomas, as assessed by 
microvessel density. In comparison, hypovascularity of cholangiocarcinoma may be 
related to a downregulation of VEGF together with an upregulation of the angiogenesis 
inhibitor thrombospondin- 1.[10] Interestingly, VEGF -A expression was more frequently 
encountered in peripheral cholangiocarcinoma (69 vs 25%, p < 0.0001) and correl ated 
with increased vascular density. [11] This could suggest a potential benefit for 
antiangiogenic therapies in peripheral cholangiocarcinomas.  
Based on the pre-cl inical data, VEGF inhibitors have been studied in bile duct cancers. 
Bevacizumab, a monoclonal antibody to VEGF, has been used in combination with 
gemcitabine/oxaliplatin or erlotinib and has shown promising results. [12, 13] The 
combination of gemcitabine and oxaliplatin with the addition of bevacizumab for first line 
treatment showed impressive overall survival of 12.7 months and progression free survival 
of 7.0 months. [12] Bevacizumab has also been studied in combination with erlotinib as a 
second line treatment. [14] The results were modest with response rate of 13% and overall 
survival of 4 months.    
Tyrosine kinase inhibitors (TKI) of VEGF have also been tested in advanced biliary tract 
tumors. Sorafenib, a small molecule inhibitor of several protein kinases including VEGFR  
has been studied as first line treatment in biliary cancers. So far there have been 2 studies 
using sorafenib in advanced biliary cancers. [15, 16] The results were moderately effective 
but with a high rate of toxicity.  
Raf-MEK-ERK Pathway  
The Raf -MEK -ERK signaling pathway controls fundamental cellular processes including 
proliferation, differentiation and survival. [17] T his pathway is an impor tant mediator of  
response to growth signals and ang iogenic factors, and is  ofte n aberrantly activated in 
huma n tumors  due to the presence of activate d RAS, mu tant BRAF , or overe xpression of  
growth factor recep tors.[18] Activated RAS triggers the phosphorylation and activation of 
the RAF kinase, which then phosphorylates MEK1 and MEK2 on two serine residues. [19] 
Because this pathway is frequently dysregulated in human cancers, intense efforts are under way to develop selective inhibitors of the ERK pathway as anticancer  drugs. In 
preclinical data, MEK inhibitors have been shown to improve survival in mice with KRAS mutant BC . [20] However,  the frequency of RAS and RAF mutations  in biliary cancer is still 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  11 of 59 
 
unclear.  In one study evaluating 69 patients wit h BC, 31 (45%) patients had KRAS 
mutations. [21] Other studies have shown RAS mutation in BC ranging from 3- 54% [22, 23]  
Incidence of BRAF mutation in BC is unclear as well. In one study, BRAF  mutations were 
identified in 22% of human cholangiocarcinoma samples. Si gnificantly, these mutations 
were mutually exclusive of KRAS alterations, which occurred in 45% of tumors within the 
same series. [21] BRAF  mutations are frequently associated enhanced sensitivity to MEK 
inhibition and may constitute a key survival mechanism for those cells. [24, 25] A better 
understanding of the frequency and impact of BRAF mutations in cholangiocarcinoma is 
needed since other studies have found no BRAF mutations in BC. [26] 
Downstream of BRAF, the MAPK pathway appears active in 75% of BC, as evidenced by P-MAPK immunostaining. [27] Expression profiling across a panel of seven human BC cell 
lines demonstrated expression of a number of RAS/MAPK pathway components and have demonstrated sensitivity to MEK inhibitors. [28]  
The PDGFR pathway also appears to be a potential target in BC. It has been hypothesized that PDGFR activation mediates resistance apoptosis. Data in human cells has shown increased sensitivity to apoptotic agents once the PDGFR - ß /c-kit pat hway 
was targeted.[ 29] 
 
1.2 Rationale of the study  
 The outcome of patients with advanced biliary cancer remains dismal with the current standard of care options. There is currently an unmet medical need for patients with 
advanced BC who have failed one prior  systemic therapy . 
The second line setting therefore offers a unique opportunity to evaluate the activity of relevant molecularly targeted therapies and to identify potential predictive biomarkers. The 
fact that aberrant activation of the Ras/Raf/MAPK pathway occurs in more than 60% of BC indicates the importance of these pathways in biliary carcinogenesis and highlights potential new strategies in the treatment of this disease. [30]  Furthermore anti -angiogenic 
agents such as the VEGF- antagonist bevacizumab, and the multikinase inhibitor sorafenib 
have been tested in BC in the first line setting with modest  activity.  
Regorafenib is  an oral multi-kinase in hibitor that targe ts both r ecep tor tyrosine kinases 
(RTKs), as we ll as the tu mor cell pro liferat ion/survival signa ling pathway kinases 
(RAS/R AF/MEK/ERK ). In addition, regorafenib inhibits VEGFR- 2/3, TIE-2, c-KIT , and 
PDG FR-ß receptor phosphor ylation.  Given the pivotal role of VEGF, the Ras/Raf/MAPK 
pathway, and PDGFR- ß in biliary cancer biology, evaluation of the regorafenib in the 
second line setting represents a rational approach.  
  . 
1.3 Regorafenib  
Regorafenib has potent preclinical antitumor activity and long -lasting anti -angiogenic 
activity as measured by dynamic contrast enhanced (DCE) – magnetic resonance imag ing 
(MRI) .  
Regorafenib is 
 a small molecule inhibitor of multiple membrane- bound and intrac ellular 
kinases involved in normal cellular functions and in pathologic processes such as 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  12 of 59 
 
oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment.  In in 
vitro biochemical or cellular assays, regorafenib or its major human active metabolites M -2 
and M -5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR -alpha, 
PDGFR- beta, FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF- 1, BRAF, BRAFV600E, 
SAPK2, PTK5, and Ab1 at concentrations of regorafenib that have been achieved 
clinically.  In in vivo  models, regorafenib demonstrated anti -angiogenic activity in a rat 
tumor model, and inhibition of tumor growth as well as anti -metastatic activity in several 
mouse xenograft models including some for human colorectal carcinoma.  
1.3.1 Preclinical  
In vivo, regorafenib exhibited anti -angiogenic and anti- proliferative effects in human colon 
and breast xenografts as demonstrated by a reduction in microvessel area, reduced Ki -67 
staining, and reduced pERK1/2 staining in tissue sections from tumor xenografts, and dose- dependent inhibition of growth in multiple xenograft models (breast, colon, renal, 
NSCLC, melanoma,  pancreatic, thyroid, ovarian). [31]  Immunohist ochemical ex -vivo 
studies with a phospho –specific monoclonocal anti- ERK 1 / 2 antibody demonstrated 
inhibition of the MAPK pathway five days after treatment with regorafenib in 2 of 3 tumor models examined (MDA -MB 231 and BxPC -3), but not in NSCLC  (H460).  
In addition, all tested human tumor xenografts (MDA -MB-231, H460, BxPC -3 and Colo-
205) demonstrated a significant reduction in new blood vessels by histomorphometry as detected in tumor samples using a murine CD31 antibody. [31] These data suggest that 
regorafenib can target the tumor cell MAPK pathway (tumor cell survival) and tumor vasculature in some but not all tumors.  
1.3.2 Clinical experience 
Two phase III global randomized studies have evaluated the efficacy of regorafenib. The CORRECT (Patients with metastatic colorectal cancer treated with re
gorafenib or placebo 
after failure of standard therapy)  trial is an international, multicenter, randomized, double-
blind, placebo- controlled study that enrolled 760 patients with mCRC whose disease has 
progressed after approved standard therapies. [32]Metastatic colorectal cancer patients 
were randomized to regorafenib plus best supportive care (BSC) or placebo plus BSC. 
Treatment cycles consisted of 160 mg of regorafenib (or matching placebo) once daily for three weeks on / one week off plus BSC. The primary endpoint of this trial was overall survival. Secondary endpoints included progression- free survival, objective tumor 
response rate and disease control rate. The safety and tolerability of the two treatment groups were also compared.  
 At a preplanned second interim analysis, there was a statistically significant survival benefit for regorafenib. The estimated hazard ratio for overall survival was 0.773 (95% confidence interval [CI], 0.635 to 0.941; 1- sided p = .0051). Patients treated with 
regorafenib had a median overall survival of 6.4 months, compared with 5.0 months for placebo — a 29% increase in survival. In addition to improved overall survival, 
progression- free survival was  superior; median progression- free survival was 1.9 months 
(95% CI, 1.88 to 2.17) for regorafenib and 1.7 months (95% CI, 1.68 to 1.74) for placebo. The estimated hazard ratio for progression- free survival was 0.493 (95% CI, 0.418 to 
0.581; 1- sided p< .000001). There was a substantial difference in disease control rate in 
the regorafenib and placebo groups (44% vs. 15%; p<.000001).  Regorafenib 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  13 of 59 
 
demonstrated comparable efficacy benefits across patient subgroups analyzed including 
age, number of mets, number of lines of prior therapy, and kras status.  
The most frequent grade 3+ adverse events in the regorafenib group were hand– foot skin 
reaction (17%), fatigue (15%), diarrhea (8%), hyperbilirubinemia (8%), and hypertension 
(7%).  The efficacy and safety from the CORRECT study supported FDA approval in 
September 2012.  
The efficacy and safety of regorafenib were examined in the P hase III GRID trial in 
patients with gastrointestinal stromal tumors (GISTs) who had exhausted all other treatment options. The study involved 199 patients with metastatic and/or unresectable GIST that had become resistant to imatinib and sunitinib. Patients were randomized 2:1 to regorafenib (160 mg orally once daily on a 3 weeks on/1 week off cycle) or placebo, plus best supportive care.  
The results showed that treatment with regorafenib led to a statistically significant 3.9-month improvement in progression- free survival (PFS),  compared with placebo (4.8 
months vs. 0.9 months; hazard ratio [HR] = 0.27;  p <.0001). Overall survival was 
statistically similar between groups as expected due to a trial design that allowed 
crossover to regorafenib for disease progression.  The median survival period without tumor growth among patients on regorafenib was 4.8 months while for the control group on placebo it was less than a month. The overall disease control rate combining partial 
responses with durable stable disease for at least 12 weeks was 53% with regorafenib compared with 9% in the control group. The most common grade ≥3 adverse events associated with regorafenib were hand- foot skin reaction (56.1%), hypertension (48.5%), 
and diarrhea (40.9%).   GRID study data is currently under FDA review.  
 
2. Study objectives 
 
Primary Objective  
• To determine 6 month overall  survival  in patients with advanced refractory BC receiving 
regorafenib. 
 Secondary Objectives 
• To determine the frequency and severity of adverse events and tolerability of the 
regimen in patients with advanced refractory BC receiving r egorafenib  
• To evaluate the disease control rate (CR + PR+ SD) as defined by the RECIST 1.1 
criteria in patients with advanced refractory biliary cancers (BC) receiving 
regorafenib at 8 weeks.  
• To determine the progression- free survival in patients with advanced refractory BC 
receiving r egorafenib  
 
Exploratory Objective 
• To explore potentia l correlat ions betw een blood bi omarke rs and clini cal benefit 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  14 of 59 
 
3. Investigator [s] and other study participants 
 
 Nishi Kothari M.D. 
 H. Lee Moffitt Cancer Center  
           Tampa, Fl  
            Hanna Sanoff M.D 
           University of North Carolina 
           Chapel Hill, NC 
                                             
            
            
            Tanios Sabb M.D 
           Ohio State University  
           Columbus , Oh 
            Andrew Poklepovic M.D 
           
VCU Massey Cancer Center  
           Richmond, VA 
            Andrew Nixon PhD  
          Duke University  
          Durham, NC  
    
4. Study design 
This is a multi- institutional single arm , Simon’s two- stage trial using regorafenib as a 
single agent in patients who have failed at least one prior line of systemic therapy in advanced biliary tumors. 39 patients will be accrued. Patients will receive regorafenib 160 
mg QD (21 days on and 7 days off). After 2 cycles (1cycle= 28 days),  response and 
progression will be evaluated using the new international  criteria proposed by the revised 
Response Evaluation Criteria in Solid Tumors (RECIST)  guidelines (version 1.1) . Primary 
endpoint is 6 month overall survival.  
  
4.1 Eligibility  
4.1.1 Inclusion criteria 
  
• Patients must have histologically or cytologically documented carcinoma primary to 
the intra- or extra- hepatic biliary system or gall bladder with clinical and/or 
radiologic evidence of unresectable, locally advanced or metastatic disease. 
Patients with ampullary carcinoma are not eligible.  
• Patients  must have failed no more than 2 prior line of systemic chemotherapy for 
advanced biliary cancer. Patients who received adjuvant chemotherapy and had 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  15 of 59 
 
evidence of disease recurrence within 6 months of completion of the adjuvant 
treatment are also eligible. If patient received adjuvant treatment and had disease recurrence after 6 months, patients will only be eligible after failing one line of systemic chemotherapy used to treat the disease recurrence.  
• Age ≥  18 years.  
• Eastern Cooperative Oncology  Group (ECOG) Performance Status Assessment of 
0 or 1  
• Measurable and non- measurable disease will be allowed.  
• Patients must not have been treated with any  VEGF inhibitors.  
• Life expectancy of at least 12 weeks (3 months).  
• For patients who have received prior cryotherapy, radiofrequency ablation, 
therasphere, ethanol injection, transarterial chemoembolization (TACE) or photodynamic therapy, the following cri teria must be met: 28 days have elapsed 
since that therapy (lesions that have not been treated with local therapy must be present and measureable 
• Subjects must be able to understand and be willing to sign the written informed 
consent form.  A signed informed consent form must be appropriately obtained 
prior to the conduct of any trial -specific procedure.  
• All acute toxic effects of any prior treatment have resolved to NCI -CTCAE v4.0 
Grade 1 or less at the time of signing the Informed Consent Form (ICF).  
• Adeq uate bone marrow, liver and liver function as assessed by the following 
laboratory requirements:  
o Total bilirub in ≤ 2.0  x the upper limits of normal (ULN)  
o Alanine aminotransferase (ALT) and aspartate amino- transferease (AST)  
≤ 2.5 x ULN (≤ 5 x ULN for subjects with liver involvement of their cancer)  
o Alkaline phosphastase limit ≤ 2.5 x ULN (≤ 5 x ULN for subjects w ith liver 
involvement of their cancer)  
o Serum creatinine  ≤ 1.5 x the ULN  
o Calculated creatinine clearance > 30 ml/min.  
 
Calculated creatinine clearance = 
(140 – age) x t (kg) x [0.85 (if 
female)]  
      72 x creatinine (mg/dL)  
 
o International normalized ratio (INR)/ Partial thromboplastin time (PTT) ≤  
1.5 x ULN. (Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  16 of 59 
 
stable based on a measurement that is pre- dose as defined by the local 
standard of care.  
 Platelet count ≥ 75,000 /mm3,  
 hemoglobin (Hb) ≥ 9 g/dL,  
 absolute neutrophil  count (ANC)  1000/mm3.  
  Blood transfusion to meet  the inclusion criteria will  be allowed.  
• Women of childbearing potential must have a negative serum pregnancy test 
performed within 7 days prior to the start of study drug.  Post -menopausal women 
(defined as no menses for at least 1 year) and surgically sterilized women are not 
required to undergo a pregnancy test.  
• Subjects (men and women) of childbearing potential must agree to use adequate 
contraception beginning at the signing of the ICF until at least 3 months  after the 
last dose of study drug.  The definition of adequate contraception will be based on 
the judgment of the principal investigator or a designated associate.  
• Subject must be able to swallow and retain oral medication.  
4.1.2 Exclusion criteria 
• Previ ous assignment to treatment during this study .  Subjects permanently 
withdrawn from study participation will not be allowed to re- enter study.  
• Other investigational treatment during or within 21 days before starting study 
treatment  
• Child Pugh B or C 
• Uncont rolled hypertension (systolic pressure >140 mm Hg or diastolic pressure 
> 90 mm Hg [NCI -CTCAE v4.0] on repeated measurement) despite optimal 
medical management.  
• Active or clinically significant cardiac disease including:  
o Congestive heart failure – New York  Heart Association (NYHA)  > Class II.  
o Active coronary artery disease.  
o Cardiac arrhythmias requiring anti -arrhythmic therapy other than beta 
blockers or digoxin.  
o Unstable angina (anginal symptoms at rest), new -onset angina within 3 
months, or myocardial infarction within 6 months.  
• Evidence or history of bleeding diathesis or coagulopathy . 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  17 of 59 
 
• Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to 
start of study medication.  
• Subjects with thrombotic, embolic, venous, or arterial events, such as 
cerebrovascular accident (including transient ischemic attacks)  deep vein 
thrombos is or pulmonary embolism within  6 months of informed consent.  
• No active malignancy except for nonmelanoma skin cancer or in situ cervical 
cancer.  Subjects surviving a cancer that was curatively treated and without 
evidence of disease for more than 3 years before the trial are allowed.  All cancer  
treatments must be completed at least 3 years prior to study entry ( i.e., signature 
date of the informed consent form).  
• Patient s with phaeochromocytoma. 
• Known history of human immunodeficiency virus (HIV) infection or current chronic 
or active hepatitis B or C infection requiring treatment with antiviral therapy.  
• Ongoing infection > Grade 2 NCI-CTCAE v4 .0. 
• Symptomatic metastatic brain or meningeal tumors.  
• Presence of a non- healing wound, non- healing ulcer, or bone fracture. 
• Renal failure requiring hemo- or peritoneal dialysis . 
• Patients with seizure disorder requiring medication. 
• Persistent proteinuria ≥ Grade 3 NCI -CTCAE v4.0 (> 3.5 g/24 hrs, measured by 
urine protein:creatinine ratio on a random urine sample).  
• Interstitial lung disease with ongoing signs and symptoms at the time of informed 
consent .  
• Pleural effusion or ascites that causes respiratory compromise ( ≥ NCI-CTCAE 
version 4.0 Grade 2 dyspnea).  
•   History of organ allograft  (including corneal transplant) . 
•   Known or suspected allergy or hypersensitivity to any of the study drugs, study 
drug classes, or excipients of the formulations given during the course of this trial.  
•   Any malabsorption condition.  
•   Women who are pregnant or breast -feeding.  
•   Any condition which, in the investigator’s opinion, makes the subject unsuitable for 
trial participation. 
•   Substance abuse, medical, psychological or social conditions that may interfere 
with the subject’s participation in the study or evaluation of the study results.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  18 of 59 
 
4.1.3 Excluded therapies and medications, previous and concomitant  
• Concurrent anti- cancer therapy (chemotherapy, radiation therapy, surgery, 
immunotherapy, biologic therapy, or tumor embolization) other than study 
treatment  
• Prior use of regorafenib or other anti VEGF drugs.  
• Concurrent use of another investigational drug or device therapy ( i.e., outside of 
study treatment) during, or within 21 days of trial entry (signing of the informed 
consent form).  
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days 
before start of study medication.  
• Use of any herbal remedy ( e.g. St. John’s  wort [Hypericum perforatum] ) 
4.2 Withdrawal of subjects from study  
4.2.1 Withdrawal 
Subjects must be withdrawn from the trial (treatment and procedures) for the following 
reasons:  
• Subject withdraws consent from study treatment and study procedures.  A subject 
must be removed from the trial at his/her own request or at the request of his/her legally acceptable representative.  At any time during the trial and without giving reasons, a subject may decline to participate further.  The subject will not suffer any disadvantage as a result.  
• Pregnancy.  Pregnancy will be reported as an SAE.  (Note: subjects who have 
been withdrawn from treatment with study drug because of pregnancy should not undergo CT scans [with contrast]/MRI or bone scans while pregnant.)  
• If, in the investigator's opinion, continuation of the trial would be harmful to the 
subject's well -being.  
• Subject is lost to follow -up. 
• Progression of disease 
• Death.  
 
Subjects  may be withdrawn from the study for the following reasons:  
• The subject is non- compliant with study drug, trial procedures, or both; including 
the use of anti -cancer therapy not prescribed by the study protocol.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  19 of 59 
 
• Severe allergic reaction to regorafenib (such as exfoliative erythroderma or Grade 
3 or 4 hypersensitivity reaction).  
• The development of a second cancer.  
• Development of an intercurrent illness or situation which would, in the judgment of 
the investigator, significantly affect assessments of clinical status and trial 
endpoints.  
• Deterioration of ECOG performance status to 3 or 4. 
• Use of illicit drugs or other substances that may, in the opinion of the invest igator, 
have a reasonable chance of contributing to toxicity or otherwise skewing trial result . 
Any subject removed from the trial will remain under medical supervision until discharge or transfer is medically acceptable.  
In all cases, the reason for withdrawal must be recorded in the CRF and in the subject's medical records.  
4.2.2 Screen Failures/Dropouts 
A subject who discontinues study participation prematurely for any reasons except death, disease 
progression and severe toxicity is defined as a dropout.
 
A sub ject who, for any reason ( e.g. failure to satisfy the selection criteria), terminates the 
study before the time point  used for the definition of “dropout” (see above) is regarded a 
“screening failure”.  
4.2.3 Replacement  
Dropout patients  will need to be replaced.   
Patients will be considered inevaluable for the primary endpoint of 6 month of OS if they 
are not able to complete first cycle.   Inevaluable patients will be replaced 
5. Treatment [s] 
5.1 Treatments to be administered 
All patients will receive regorafenib  
 
Arm 1: Regorafenib 
 
 
Agent   Dose  Route   Day Schedule*   
   
Regorafenib 160mg   PO  QD 21 days  
 
One cycle = 28days    
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  20 of 59 
 
 
5.1.1 Regorafenib 
Regorafenib tablets will be packaged in high density polyethylene bottles with a white child 
resistant closure and induction seal.   Each bottle includes 30 tablets and a 3- gram 
desiccant.  The bottles will have a label affixed containing study identification, product identification, and quantity of tablets.  Once the drug has been received it must be kept in a secure, dry location.  Study drug must be stored in its original bottle at a temperature not above 25°C (77°F).  
The study drug must be exclusively used for the investigation specified in this protocol and it will only be accessible to authorized staff.  
5.1.2 Dosage and administration: 
Regorafenib tablets for oral administration are formulated as light pink oval shaped tablets  
debossed with “BAYER” on one side and “40” on the other.  Each tablet contains 40 mg of regorafenib in the anhydrous state, which corresponds to 41.49 mg of regor afenib 
monohydrate, and the following inactive ingredients: cellulose microcrystalline, croscarmellose sodium, magnesium stearate, povidone, and colloidal silicon dioxide.   The film –coating contains the following inactive ingredients: ferric oxide red, ferric oxide 
yellow, lecithin (soy), polyethylene glycol 3350, polyvinyl alcohol, talc, and titanium dioxide.  
5.1.3 Study Treatment  
Regorafenib is administered as  monotherapy during the study, 160 mg qd will be 
administered for 3 weeks on /1 week off.   One cycle is 28 days.  
 Four 40- mg regorafenib tables should be taken in the morning with approximately 8 fluid 
ounces (240 mL) of water after a low -fat (<30% fat) breakfast.   Some examples of low fat 
breakfasts are:  
• Two slices of white toast with 1 tablespoon of low- fat margarine and 1 tablespoon 
of jelly and 8 ounces (240 mL) of skim milk (approximately 319 calories and 8.2 g of fat).  
• One cup of cereal ( i.e. Special K), 8 ounces (240 mL) of skim milk, one piece of 
toast with jam (no butter or marmalade), apple juice, and one cup of coffee or tea (2 g fat, 17 g protein, 93 g of carbohydrate, 520 calories.  
5.1.4 Dose Modification for management of adverse events 
5.1.4.1 Dose Reduction Levels 
The starting dose of regorafenib is 160 mg once daily.  Study medication will be 
administered on a 3 weeks on/1week off schedule [3 weeks out of every 4] . 
Doses will be delayed or reduced for clinically significant hematologic and non-hematologic toxicities that are related to protocol therapy according to the guidelines shown in the Dose Delays/Dose Modifications table that follows.  Dose modifications will 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  21 of 59 
 
follow predefined dose levels . Dose adjustments for hematologic toxicity are based on the 
blood counts obtained in preparation for the day of treatment.  
The modifications of regorafenib will follow the following predefined dose levels:  
Dose level 0 
(standard starting 
dose ) 160 mg po qd Four 40- mg tablets of regorafenib 
Dose level - 1 120 mg po qd  Three 40- mg tablets of regorafenib 
Dose level - 2 80 mg po qd  Two 40- mg tablets of regorafeni b 
 
If a subject experiences more than one toxicity, dose reduction should be according to the 
toxicity with the highest grade  
In the case of two or more toxicities of the same grade, the investigator may dose reduce according to that deemed most causally  related to study treatment  
 If more than 2 dose reductions are required, regorafenib will be discontinued and patient 
will need to come off of the trial.   If a dose reduction has been performed, intra- subject 
dose re- escalation can be considered (up to the maximal 160 mg daily dose) at the 
discretion of the treating physician provided that the toxicity(ies) has resolved to baseline.  
 The following tables outline dose adjustments for toxicities related to study drug except hand- foot skin reaction, hypertension and liver function test abnormalities.  
 
 
Table 6-1:  Recommended dose modificat ion for toxicities except hand -foot-skin 
reaction, hypertension and ALT/ST/bilirubin  
NCI-CTCAE v4.0a Dose Interruption  Dose  
Modification b Dose for 
Subsequent 
Cycles 
Grade 0 -2 Treat on time  No change  No change  
Grade 3  Delay until ≤ Grade 
2c Reduce by 1 dose 
level If toxicity remains < 
Grade 2, dose re-
escalation can be considered at the discretion of the treating investigator. If dose is re-escalated and toxicity ( ≥ Grade 3) 
recurs, institute permanent dose 
reduction.  
Grade 4  Delay until ≤ Grade 
2c Reduce by 1 dose 
level.  
Permanent discontinuation 
can be considered 
at  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  22 of 59 
 
treating 
investigator’s  
discretion.  
a. NCI -CTCAE = National Cancer Institute - Common Terminology Criteria for Adverse 
Events,  
    version 4.0 
b. Excludes alopecia, non- refractory nausea/vomiting, non- refractory hypersensitivity 
and nonclinical and asymptomatic laboratory abnormalities.  
c. If no recovery after  a 4 week delay*, treatment should be permanently discontinued 
unless subject is deriving clinica l benefit.  
*   Modify according to study specific cycle length 
 
The table above outlines dose adjustments for hematologic and non- hematologic toxicities 
related to regorafenib except HFSR and hypertension.  
In addition to these recommended dose modifications, subjects who develop diarrhea,  
mucositis, anorexia or other events predisposing to fluid loss or inadequate fluid intake 
should be carefully monitored and rehydrated as clinically necessary.  This is in order to minimize the risk of postural hypotension and renal failure.  
                         
Table 6-2: Grading for Hand -Foot-Skin-Reaction  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  23 of 59 
 
 Grade 1 Grade 2 Grade 3 
NCI-CTCAE v4.0 
Palmar -plantar 
erythrodysesthesia 
syndromea Minimal skin changes 
or dermatitis (e.g., erythema, 
edema, or hyperkeratosis)  
without pain  Skin changes 
(e.g., peeling, 
blisters  bleeding, edema, or hyperkeratosis) 
with pain  Severe skin 
changes ( e.g., 
peeling, blisters, bleeding, edema, or hyperkeratosis) 
with pain  
Further description / 
examples of skin changes  Numbness, 
dysesthesia / paresthesia tingling, 
painless swelling, or erythema of the hands 
and/or feet  Painful erythema 
and swelling of the hands and/or feet  Moist 
desquamation, ulceration, blistering, or severe pain of the 
hands and/or feet  
Effect on activities  Does not d isrupt 
normal activities  Limiting 
instrumental activities of daily life (e.g., preparing 
meals, shopping for groceries or clothes, using the telephone, 
managing money)  Limiting self -care 
activities of daily life (e.g., bathing, 
dressing and undressing, feeding self, using the toilet, taking  
medications) and 
not bedridden  
a. Palmer -planter erythrodysesthesia syndrome is a disorder c haracterized by redness, 
marked 
    discomfort, swelling, and tingling in the palms of hands or the soles of the feet.  
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  24 of 59 
 
 
 
Table 6.3  Recommended dose modification for hand- foot-skin reactiona 
Grade of event  
(NCI-CTCAE v4.0)  Occurrence  Suggested Dose Modification  
Grade 1  Any Maintain dose level  and immediately institute 
supportive measures for symptomatic relief  
Grade 2  
 1st occurrence  Consider decreasing dose by one dose level and 
immediately institute supportive measures.  If no 
improvement, interrupt therapy for a minimum of 7 
days, until toxicity resolves to Grade 0 -1 b, c 
No 
improvement 
within 7 days or 
2nd occurrence  Interrupt therapy until toxicity resolves to Grade 0 -
1.c 
When resuming treatment, treat at reduced dose 
level b 
3rd occurrence  Interrupt therapy until toxicity resolves to Grade 0 -
1. c 
When resuming treatment, decrease dose by one 
dose level . b, d 
4th occurrence  Discontinue therapy  
Grade 3  
 1st occurrence  Institute supportive measures immediately. 
Interrupt  therapy for a minimum of 7 days  until 
toxicity resolves  to Grade 0-1. c When resuming 
treatment, decrease dose by one dose level . b, d 
2nd occurren ce Institute supportive measures immediately. 
Interrupt therapy for a minimum of 7 days until 
toxicity resolves to Grade 0- 1. c When resuming 
treatment, decrease dose by one additional dose 
level b, d  
3rd occurrence  Discontinue treatment permanently . 
a. More conservative management is allowed if judged medically appropriate by the 
investigator.  
b. If toxicity returns to Grade 0- 1 after dose reduction, dose re- escalation is permitted at the 
discretion of the investigator if subject has completed one cycle at reduced dose without 
recurrence of event.  
c. If there is no recovery after a 4- week delay, treatment with regorafenib will be discontinued 
permanently.  
d. Subjects requiring > 2 dose reductions should go off protocol therapy.  
e. The maximum daily dose is 160 mg.  
  
 
    
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  25 of 59 
 
 
At first occurrence of HFSR, independent of grade, prompt institution of supportive 
measures such as topical emollients, low potency steroids, or urea- containing 
creams should be administered.  
Recommended prevention/management strategies for skin toxicities consistent with HFSR 
are summarized below:  
Control of calluses 
Before initiating treatment with regorafenib:  
• Check condition of hands and feet . 
• Suggest a manicure/pedicure, when indicated. 
• Recommend pumice stone use for callus or ‘rough spot’ remov al. 
During regor afenib treatment: 
• Avoid pressure points . 
• Avoid items that rub, pinch or create friction. 
Use of creams 
• Non-urea based creams may be applied liberally . 
• Keratolytic creams (e.g. urea- based creams, salicylic acid 6%) may be used 
sparingly and only to affected (hyperkeratotic) areas.  
• Alpha hydroxyl acids (AHA) based creams may be applied liberally 2 times a day.  
Approximately 5% to 8% provides gentle chemical exfoliation.  
• Topical analgesics (e.g. lidocaine 2%) are to be considered for pain cont rol. 
• Topical corticosteroids like clobetasol 0.05% should be considered for subjects 
with Grade 2 or 3 HFSR.  Avoid systemic steroids.  
Tender areas should be protected as follows:  
• Use socks/gloves to cover moisturizing creams  
• Wear well -padded footwear  
• Use insole cushions or inserts (e.g. silicon, gel)  
• Foot soaks with tepid water and Epson salts  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  26 of 59 
 
 
Hypertension 
Hypertension is a known AE associated with regorafenib treatment.  Subject will have their 
blood pressure measured at least weekly at the study site during the first 6 weeks of treatment.  If additional blood pressure measurements are done outside the study site, and the blood pressure is > 140 mm Hg systolic or > 90 mm Hg diastolic  (NCI CTCAE 
v4.0) , then the subject must contact study personnel.  The management of hypertension, 
including the choice of antihypertensive medication, will be performed according to local standards and to the usual practice of the investigator.  Every effort should be made to control blood pressure by medical means other than study drug dose modification.  If necessary, Table 6.4 outlines suggested dose reductions.  
 
                         
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  27 of 59 
 
Table 6-4:  Management of Treatment -Emergent Hypertension  
Grade   
(CTCAE v4.0)  Antihypertensive Therapy  Regorafenib Dosing  
1 
 
Prehypertension 
(systolic BP  
120 - 139 mmHg or 
diastolic  
BP 80 - 89 mmHg)  None • Continue regorafenib 
• Consider increasing blood pressure (BP) monitoring  
2 
 
Systolic BP 140 - 159 
mmHg  
or diastolic BP 90 - 99 
mmHg, OR 
Symptomatic increase by 
> 20 mmHg (diastolic) if  
previously within normal 
limits  • Treat with the aim to 
achieve diastolic BP ≤ 90 mm Hg: 
• If BP previously within normal limits, start anti -
hypertensive monotherapy  
• If patient already on anti-hypertensive medication, titrate up the dose.  • Continue regorafenib 
 
• If symptomatic, hold regorafenib until symptoms resolve AND 
diastolic BP ≤ 90 mm Hg
a. When 
regorafenib is restarted, continue at the same dose level.  
 
3 
 
Systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg  
OR 
More than one drug or more  
intensive therapy than previously used indicated Treat with the aim to achieve diastolic BP ≤ 90 mm Hg: Start anti -hypertensive 
medication  
 
AND/OR 
Increase current anti -
hypertensive medication 
 
AND/OR  
Add additional anti -
hypertensive medications.   • Hold regorafenib until diastolic BP 
≤ 90 mm Hg, and if symptomatic, 
until symptoms resolve.a 
 
• When regorafenib is restarted, 
continue at the same dose level.  
 
• If BP is not controlled with the 
addition of new or more intensive therapy, reduce by 1 dose level .
b 
 
• If Grade 3 hypertension recurs 
despite dose reduction and antihypertensive therapy, reduce 
another dose level .c 
4 
 
Life-threatening 
consequences  
(eg, malignant hypertension,  
transient or permanent  
neurologic deficit,  
hypertensive crisis)  Per institutional guidelines  Discontinue therapy  
a. Patients requiring a dela y of >4 weeks should go off protocol therapy  
b. If BP remains controlled for at least one cycle, dose re- escalati on permitted per 
investigator’s discretion.  
c. Patients requiring >2 dose reductions should go off protocol therapy. 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  28 of 59 
 
 
 
 
  Liver Function Abnormalities  
For patients with observed worsening of serum liver tests considered related to 
regorafenib (i.e. where no alternative cause is evident, such as post -hepatic cholestasis or 
disease progression), the dose modification and monitoring advice in Table 6- 5 should be 
followed.  
 Regorafenib is a UGT1A1 inhibitor.  Mild, indirect (unconjugated) hyperbilirubinemia may  
occur in patients with Gilbert’s syndrome.  
  Alanine or aspartate aminotransferase (AST/ALT): for any grade increase in AST or ALT, the investigator needs to ensure that it is not due to biliary obstruction or the introduction of new drugs. Biliary obstruction should be ruled out by imaging if needed. If the elevation of AST or ALT is due to biliary obstruction, and the biliary obstruction is treated, the study drug may be restarted at the same dose level upon return of the AST and ALT to baseline or grade 2.  
 For any grade increase in bilirubin, the investigator needs to ensure that it is not due to biliary obstruction or the introduction of new drugs. Biliary obstruction should be ruled out by imaging if needed. If the elevation of bilirubin is due to biliary obstruction, and the biliary obstruction is treated, the study drug may be restarted at the same dose level upon return of the bilirubin to baseline or Grade 1.  
    
Table 6-5:  Dose modifications/interruption for ALT and/or AST and/or bilirubin 
increases related to study drug  
Observed elevations 1st Occurrence Restart Re-occurrence 
ALT and/or AST >5 X 
ULN (≥ G3)  If patient had Grade 
0 or 1 AST or ALT 
increase at baseline, hold the drug until AST or ALT returns to Grade 1 or baseline. 
 
If patient had Grade 2 (asymptomatic) AST or ALT increase at baseline, continue treatment at same dose and follow AST or ALT weekly 
for 4 weeks. Hold Reduce one dose level 
and measure serum liver tests weekly for at least 4 weeks.  Discontinue  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  29 of 59 
 
the drug  if patient 
develops symptoms 
or if AST or ALT > 
10 x IULN;  
restart treatment with one dose level reduction when AST or ALT returns to baseline AND patient is asymptomatic  
 
ALT and/or AST > 20 
X ULN (≥ G4)  Discontinue    
Bilirubin ( G=2)  If patient had a 
normal bilirubin at baseline, hold the drug until bilirubin returns to Grade 1 or baseline 
 
If patient had Grade 1 bilirubin at baseline, continue treatment at sam e 
dose and follow bilirubin weekly for 4 weeks. Hold the drug if patient develops symptoms or if bilirubin > 2 x ULN and AST or ALT > 5 x ULN  
Restart treatment when bilirubin returns to grade 1 or baseline and patient 
is asymptomatic.  Restart with one dos e 
reduction Discontinue  
Bilirubin ( G=3)  Discontinue   Discontinue  
During the first 2 cycles of treatment, ALT, AST and bilirubin must be monitored every 2 
weeks . 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  30 of 59 
 
Bilirubin and AST/ALT: for any grade increase in bilirubin AST or ALT, the investigator 
needs to ensure that it is not due to biliary obstruction or the introduction of new drugs. 
Biliary obstruction should be ruled out by imaging if needed. If the elevation of AST or ALT is due to biliary obstruction, and the biliary obstruction is treated, the study drug may be 
restarted at the same dose level upon return of the AST and ALT to baseline or grade 2.  
 
  
 
 
5.1.4.2 Prevention/management strategies for diarrhea 
Diarrhea can be a common side effect of regorafenib.   The same dose- modification 
algorithm used for skin toxicities can be used to address these toxicities.  However, the 
preventive/management strategies for diarrhea should be consistent with local standards (e.g., anti -diarrheals and optimized hydration status).  
Anti-diarrhea medications may be introduced if symptoms occur.  Previous trials have 
shown that the diarrhea could be managed with loperamide.  The recommended dose of loperamide is 4 mg at first onset, followed by 2 mg every 2 to 4 hours until diarrhea- free 
for 12 hours.  
5.2 Drug logistics and accountability  
All study drugs will be stored at the investigational site in accordance with Good Clinical Practice (GCP) and Good Manufacturing Practices ( GMP ) requirements and the 
instructions given by the clinical supplies department of the Institution  and will be 
inaccessible to unauthorized personnel.  
5.2.1 Accountability  
The investigator, or a responsible party designated by the investigator, must maintain a careful record of the inventory and disposition of the agent (investigational or free of charge) using the NCI Drug Accountability Record or another comparable drug accountability form. (See the CTEP website at http://ctep.cancer.gov/protocolDevelopment
  
for the “Policy and Guidelines for Accountability and Storage of Investigational Agents” or to obtain a copy of the drug accountability form.)  
5.2.2 Destruction and Return 
At the end of the study, unused supplies of regorafenib should be destroyed according to 
institutional policies. Destruction will be documented in the Drug Accountability Record Form. The certificate of destruction should be sent to Bayer.  
A completed “Unused Study Drug Disposition Form Destruction or Return Confirmation” should be sent to Bayer at the following address:   
E-mail:  Karen.marini@bayer.com  
  OR  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  31 of 59 
 
Fax: 973- 709-2193 
  OR 
Mail: (VP of Medical Affairs named in contract) at  
Bayer HealthCare Pharmaceuticals  
6 West Belt  
Wayne, NJ   07470 
5.3 Treatment compliance 
An adequate record of receipt, distribution, and return of all study drugs  must be kept in 
the form of a Drug Accountability Form.  
Subject compliance with the treatment and protocol includes willingness to comply with all 
aspects of the protocol, and to have blood collected for all safety evaluations.  At the discretion of the principal investigator, a subject may be discontinued from the trial for 
non-compliance with follow -up visits or study drug.  
5.4 Prior and concomitant therapy  
All medication that is considered necessary for the subject’s welfare, and which is not expected to interfere with the evaluation of the study treatment, may be given at the discretion of the investigator.   All medications (including contrast media) taken within 2 
weeks prior to the start of the study and during the study must be recorded in the subject’s  
source documentation and in the CRF (including start/stop dates, dose frequency, route of administration, and indication).  Specific caution should be taken when considering or administering a concomitant medication that is metabolized by the cytochrome enzymes CYP2C8, CYP2B6 and CYP2C9.  Such concomitant medication should be avoided, if possible.  
Co-administration of a strong CYP3A4 inducer (rifampin) with a single 160 mg dose of 
Stivarga decreased the mean exposure of regorafenib, increased the mean exposure of the active metabolite M -5, and resulted in no change in the mean exposure of the active 
metabolite M -2.  Avoid concomitant use of Stivarga with strong CYP3A4 inducers (e.g. 
rifampin, phenytoin, carbamazepine, phenobarbital, and St. John’s Wort)  
Co administration of a strongCYP3A4 inhibitor (ketoconazole) with a single 160mg dose of 
Stivarga increased the mean exposure of regorafenib and decreased the mean exposure of the active metabolites M -2 and M -5.  Avoide concomitant use of Stivarga with strong  
inhibitors of CYP3A4 activity (e.g. clarithromycin, grapefruit juice, itraconazole, ketoconazole, nefazadone, posaconazole, telithromycin, and voriconazole).  
 
Permitted concomitant therapy includes:  
• Standard therapies for concurrent medical conditions . 
• Supportive care for any underlying illness . 
• Palliative radiation therapy is allowed if the target lesion(s) are not included within 
the radiation field and no more than 10% of the bone marrow is irradiated.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  32 of 59 
 
• Granulocyte colony -stimulating factor (G -CSF) and other hematopoietic growth 
factors may be used in the management of acute toxicity, such as febrile 
neutropenia, when clinically indicated or at the investigator’s discretion. However, they may not be substituted for a required dose reduction.  Subjects are permitted 
to take chronic erythropoietin.  
• Treatment with nonconventional therapies (such as acupuncture), and 
vitamin/mineral supplements are permitted provided that they do not interfere with the study endpoints, in the opinion of the investigator.  
• Bisph osphonates  
• Subjects who are therapeutically treated with an agent such as warfarin or heparin 
will be allowed to participate provided that their medication dose and INR/PTT are stable.  Close monitoring (day5 of cycle 1 and day 1 of each cycle) is mandator y.  
If either of these values are above the therapeutic range, the doses should be modified and the assessments should be repeated weekly until they are stable.  
The following are not permitted:  
• Other investigational treatment during or within 21 days before starting study 
treatment  
• Systemic antitumor therapy, including cytotoxic therapy, signal transduction 
inhibitors, immunotherapy, and hormonal therapy  
• Bone marrow transplant or stem cell rescue 
• Subjects taking narrow therapeutic index medications should be monitored 
proactively (e.g. warfarin, phenytoin, quinidine, carbamazepine, Phenobarbital, cyclosporine, and digoxin).  Warfarin is metabolized by the cytochrome enzyme 
CYP2C9 and it’s levels may be especially affect ed by regorafenib 
• Use of any herbal remedy (e.g. St. John’s wort [Hypericum perforatum])  
6. Procedures and variables 
6.1 Calendar  
 
   
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  33 of 59 
 
 
Required studies must be done within 28 days prior to starting on the treatment.  
 
1 Protocol treatment and parameters will continue at these intervals until progression of disease or until patient has met any  of the guidelines in Section 4.2.1  
2 After o ff treatment following disease progression, physical assessments (with lab tests 
performed at the discretion of the treating investigator) should take place every 3 months for up to two years or death.  
3 Sodium, potassium, chloride, CO2, calcium, magnesium, phosphorus, blood urea nitrogen [BUN], creatinine, glucose, albumin, total protein, alkaline phosphatase, bilirubin [total and direct], AST, ALT   
Cycle 1    +/- 2 Days  
Cycle 2    +/- 2 Days 
  
Cycle 31       +/- 2 Days 
REQUIRED 
STUDIES Pre-
Study  Wk 
1 
 Wk 
2  Wk
3 
 Wk 
4 Wk 
5 Wk 
6 Wk 
7 Wk 
8 Wk 
9 Wk 
10 Wk 
11 Wk 
12 Pre-
Progression Follow -
Up 1 Post-
Progression Follow -Up 
2 
PHYSICAL  1                
History and 
Physical Exam  
(informed 
consent)  X X X X X X X   X    X X 
Weight and 
Performance 
Status  X X X X X X X   X    X  
Toxicity 
Notation  X X X X X X X   X    X # X # 
Blood Pressure   X X X X X X         
LABORATORY
  1                
CBC, 
Differential, 
Platelets  X X  X  X  X  X      
CA-19-9 X         X      
Serum 
Chemistry  3 X X  X  X  X  X      
U/A 7 X               
PT/INR  X               
X-RAYS AND 
SCANS 1, 4                
CT/MRI for 
Disease 
Assessment  5 X         X    X  
EKG  X               
SPECIMEN 
SUBMISSION                 
Blood sample ( 
for 
correlatives)6 X         X      
                
TREATMENT                 
Regorafenib    X X X  X X X  X X X    
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  34 of 59 
 
4 To be performed every 8 weeks until progression.  Must be performed using same 
method as prestudy.  
5 Scan must be performed +/ - 1 week of each assessment.  
6 Dr aw 1 x10mls EDTA t ubes at baseline, Cycle 3 D ay 1 (+/- 2 days), and at the 
treatm ent disconti nuati on visit if patient continues on after cycle 3 day1.  ( see section 
13.) 
7.   Spot ur ine must not show  2+ or more  protein in urine or the pa tient will 
require a repea t urine an alysis.  If repeat u rinanalysis shows 2+ prot ein or mor e, a 
24-   hour ur ine collection will be required an d must show  total protein excre tion 
<3500 m g/24 ho urs 
  # Toxicity should be evaluated until resolution of any adverse events.  
 
6.2 Safety 
All subjects who receive at least one dose of study treatment will be valid for the safety analysis.  
All observations pertinent to the safety of the study treatment will be recorded and included in the final report.  
Safety variables include the following: AEs, laboratory changes (complete blood counts, electrolytes, chemistry, and coagulation), changes in vital signs (blood pressure, heart rate, respiratory rate, and temperature) and ECG and, in some instances, changes in 
chest x -ray images, as produced at the investigator’s discretion ( e.g., for evaluation for 
pneumonia).  
All AEs whether considered drug -related or not, will be reported with following information:  
start/stop dates, action taken, whether treatment was discontinued, any corrective measures taken, outcome, and other possible causes.  For all events, the relationship to treatment and the intensity of the event will be determined by the investigator.  
This trial will use the NCI -CTCAE v4.0 criteria for assessment of toxicity and SAE 
reporting with regard to toxicity grade.  
6.2.1 Adverse events 
Investigators should refer to the Safety Information section of the current IB for  
regorafenib,  including the DCSI (development core safety information), for the expected 
side effects of, regorafenib.  As with any agent, there is always the potential for 
unexpected AEs, including hypersensitivity reactions.  The IB will be updated if any new relevant safety data are obtained.  
Therapeutic monitoring should be performed following dose selection or modification of regorafenib,  in a manner consistent with the local clinical standard of care.  In general, 
subjects should be closely monitored for side effects of all concomitant medications regardless of the path of drug elimination.  
All concomitant medications must be recorded in the subject’s source documentation.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  35 of 59 
 
Subjects must be carefully monitored for AEs.  This monitoring also includes clinical 
laboratory tests.  Adverse events should be assessed in terms of their seriousness, intensity, and relationship to the study drug, or other chemotherapy/treatment.  
6.2.1.1 Definitions 
Definition of adverse event (AE)  
In a clinical study, an AE is any untoward medical occurrence ( i.e. any unfavorable 
and unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study.  Therefore, an AE may or may not be temporally or causally associated with the use of  a medicinal (investigational) product.  
A surgical procedure that was planned prior to the start of the study by any physician treating the subject should not be recorded as AE (however, the condition for which the surgery is  
required may be an AE  if worse ns compared to baseline).  
 
• Conditions  that started before signing of informed consent and for which no 
symptoms or treatment are present until signing of informed consent  are recorded 
as medical history ( e.g. seasonal allergy without acute complaints).  
• Conditions  that started before signing of informed consent and for which symptoms 
or treatment are present after signing of informed consent, at unchanged intensity , 
are recorded as medical history  (e.g. allergic pollinosis) . 
• Conditions  that started or deteriorated after signing of informed consent will be 
documented as adverse events . 
Definition of serious adverse event (SAE)  
An SAE is classified as any untoward medical occurrence that, at any dose, meets any of the 
following criteria (a – f): 
a. Results in death. 
b. Is life -threat ening . 
The term ‘life -threatening’ in the definition refers to an event in which the patient 
was at risk of death at the time of the event, it does not refer to an event which hypothetically might have caused death if it were more severe.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  36 of 59 
 
c. Requires inpatient hospitalization or prolongation of existing hospitalization. 
A hospitalization or prolongation of hospitalization will not be regarded as an SAE 
if at least one of the following exceptions is met:  
- The admission results in a hospital stay  of less than 12 hours . 
- The admission is pre- planned.  
(i.e. elective or scheduled surgery arranged prior to the start of the study)  
- The admission is not associated with an AE.  
(e.g. social hospitalization for purposes of respite care).  
However, it should be noted that invasive treatment during any hospitalization may fulfill the criterion of ‘medically important’ and as such may be reportable as an SAE dependent on clinical judgment.  In addition, where local regulatory authorities specifically require a more stringent definition, the local regulation takes precedence.  
d. Results in persistent or significant disability / incapacity . 
Disability  means a substantial disruption of a person’s ability to conduct normal life’s 
functions.  
e. Is a congenital anomaly / birth defect . 
f. Is another  medically important serious event as judged by the investigator . 
6.2.1.2 Classifications for adverse event assessment  
 
All AEs will be assessed and documented by the investigator according to the categories 
detail ed below.  
6.2.1.2.1 Seriousness 
For each AE, the seriousness must be determined according to the criteria given in 
Section 6.2.1.1 
6.2.1.2.2 Intensity  
The intensity of the AE is classified according to the CTCAEv4.0.  Grade refers to the 
severity (intensity) of the AE:  
CTCAEv4 Grade 1: mild; asymptomatic  or mild symptoms; clinical or diagnostic 
observations only; intervention is not indicated.  
CTCAEv4 Grade 2: moderate; minimal, local, or noninvasive intervention is indicated; 
limiting to age -appropriate instrumental activities of daily living (ADL; instr umental 
ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc) . 
CTCAEv4 Grade 3: Severe or medically significant but not immediately life 
threatening; hospitalization or prolongation of hospitalization is indicated; disabling; 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  37 of 59 
 
limiting to self care ADL (self care ADL refers to bathing, dressing and undressing, 
feeding self, using the toilet, taking medications, and not bedridden).  
CTCAEv4 Grade 4: life -threatening consequences; urgent intervention is indi cated.  
CTCAEv4 Grade 5: death due to an AE.  
6.2.1.2.3 Causal relationship  
The assessment of the causal relationship between an AE and the administration of 
treatment is a clinical decision based on all available information. 
 The causality assessment should be done separately for each study treatment . 
The assessment is based on the question whether there was a “reasonable causal 
relationship” to the study treatment in question.  
Possible answers are “yes” or “no” . 
An assessment of “no” would include:  
1. The existence of a clear alternative explanation, e.g. mechanical bleeding at 
surgical site.  
or 
2. Non-plausibility, e.g. the subject is struck by an automobile when there is no 
indication that the drug caused disorientation that may have caused the event; cancer developing a few days after the first drug administration.  
An assessment of “yes” indicates that there is a reasonable suspicion that the AE is associated with the use of the study treatment.  
Factors to be considered in assessing the relationship of the AE to study treatment include:  
- The temporal sequence from drug administration:  The event should occur after the drug is given.  The length of time from drug exposure to event should be evaluated in the clinical context of the event.  
- Recovery on drug discontinuation (de- challenge), recurrence on drug re- introduction 
(re-challenge):  
- Subject’s response after de- challenge or subjects response after re- challenge should 
be considered in the view of the usual clinical course of the event in question.  
- Underlying, concomitant, intercurrent diseases:   
Each event should be evaluated in the context of the natural history and course of the disease being treated and any other disease the subject may have.  
- Concomitant medication or treatment:  
The other drugs the subject is taking or the treatment the subject receives should be examined to determine whether any of them may be suspected to cause the event in question.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  38 of 59 
 
- The pharmacology and pharmacokinetics of the study treatment:  
The pharmacokinetic properties (absorption, distribution, metabolism and excretion) of 
the study treatment, coupled with the individual subject’s pharmacodynamics should be considered.  
[Causal relationship to protocol -required procedure(s)]  
The assessment of a possible causal relationship between the AE and protocol -required 
procedure(s) is based on the question whether there was  a “reasonable causal 
relationship” to protocol- required procedure(s).  
Possible answers are “yes” or “no” . 
6.2.1.2.4 Action taken with study treatment  
Any action on study treatment to resolve the AE is to be documented using the categories listed below.  
The study treatment action should be recorded separately for each study treatment . 
 ־Drug withdrawn 
 ־Drug interrupted 
 ־Dose reduced 
 ־Dose not changed 
 ־Dose increased 
 ־Not applicable 
 ־Unknown 
6.2.1.2.5 Other specific treatment(s) of adverse events 
 ־None 
 ־Remedial drug therapy  
6.2.1.2.6 Outcome 
The outcome of the AE is to be documented as follows:  
 ־Recovered/resolved 
 ־Recovering/resolving  
 ־Recovered/resolved with sequelae 
 ־Not recovered/not resolved 
 ־Fatal  
 ־Unknown 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  39 of 59 
 
 
7.   CRITERIA FOR EVALUATION AND ENDPOINT ANALYSIS  
This study will use the RECIST 1.1 guidelines  
7.1 Measurability of Lesions 
 
a.  Measurable disease   
  
Measurable disease is defined differently for lymph nodes compared 
with other disease and will be addressed in a separate s ection 
below.  
 
1. Lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 2.0 cm  by chest x -ray, by ≥ 1.0 cm  with CT or MRI scans, or ≥ 1.0 cm 
with calipers by clinical exam. All tumor measurements must be recorded in decimal fractions of centimeters (or millimeters).  
 
The defined measurability of lesions on CT scan is bas ed on 
the assumption that CT slice thickness is 0.5 cm or less.  If CT scans have slice thickness greater than 0.5 cm, the minimum size for a measurable lesion should be twice the slice thickness.   
 2. Malignant lymph nodes
 are to be considered pathologicall y 
enlarged and measurable if it measures ≥ 1.5 cm in SHORT 
AXIS (greatest diameter perpendicular to the long axis of the 
lymph node) when assessed by scan (CT scan slice recommended being no greater than 0.5 cm).  
 b.    Non-measurable disease
:  All other l esions (or sites of disease), 
including small lesions (longest diameter < 1.0 cm or pathologic lymph nodes with ≥ 1.0 cm to < 1.5 cm short axis), are considered non-measurable disease.  Bone lesions, leptomeningeal disease, 
ascites, pleural/pericardial eff usions, lymphangitis cutis/pulmonitis, 
inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered non- measurable as are previously 
radiated lesions that have not progressed.  
 c. 
Notes on measurability  
 
1. For CT and MRIs, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should by performed with breath- hold scanning techniques, if possible.  
 2. PET-CT:  At present, the low dose or att enuation correction 
CT portion of a PET -CT is not always of optimal diagnostic 
CT quality for use with RECIST measurements.  However, if the site can document that the CT performed as part of a PET-CT is of identical diagnostic quality to a diagnostic CT, 
then the CT portion of the PET -CT can be used for RECIST 
measurements and can be used interchangeably with conventional CT.  
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  40 of 59 
 
3. Ultrasound: Ultrasound is not useful in assessment of lesion 
size and should not be used as a method of measurement.  
 4. Cystic lesion s that meet the criteria for radiographically 
defined simple cysts should not be considered as malignant lesions (neither measurable nor non- measurable) since they 
are, by definition simple cysts.  
 
5. If a target lesion becomes very small some radiologists indicate that it is too small to measure.  If the lesion is 
actually still present, a default measurement of 0.5 cm should be applied.  If the radiologist believes the lesion has gone, a default measurement of 0.0cm should be   
 
7.2 Objective Status at Each Disease Evaluation   
Objective Status is to be recorded at each evaluation. All measurable lesions up to a maximum of 2 lesions per organ 5 lesions in total, representative of all involved organs, should be identified as target
 lesions 
at baseline. All other l esions (or sites of disease) including any measurable 
lesions over and above the 5 target lesions should be identified as non-
target  lesions.  Measurements must be provided for target measurable 
lesions, while presence or absence must be noted for non- target 
measurable and non- measurable disease.   
 For studies that use disease progression as an endpoint, whole body 
scanning at specific intervals is necessary to determine that progression is NOT present outside of the “target” areas. Therefore, in these studies it is not acceptable to image only the “target” areas of the body in follow -up 
scans. For study -specific imaging requirements, see the Study Calendar in 
Section 9.0.   
 a.  Complete Response (CR):
  Complete disappearance of all target 
and non- target lesions (with the exception of lymph nodes 
mentioned below).  No new lesions.  No disease related symptoms.   Any lymph nodes (whether target or non- target) must have 
reduction in short axis to < 1.0 cm.  All disease must be assessed using the same technique as baseline.  
 b. Partial Response (PR):
 Applies only to patients with at least one 
measurable lesion. Greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions.  No unequivocal progression of non-measurable disease.  No new lesions.  All target measurable lesions must be assessed using the same techniques as baseline.  
 c.  Stable:
 Does not qualify for CR, PR, Progression or Symptomatic 
Deterioration.  All target measurable lesions must be ass essed 
using the same techniques as baseline.  
 d.  Progression
: One or more of the following must occur:  20% 
increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline, as well as 
an absolute increase of at least 0.5 cm.  Unequivocal progression of non-measurable disease in the opinion of the treating physician (an 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  41 of 59 
 
explanation must be provided).  Appearance of any new lesion/site.  
Death due to disease without prior documentation of progression 
and without symptomatic deterioration (see Section 10.2e).  
  Notes regarding new lesions:  FDG -PET imaging can complement 
regular scans in identifying new lesions according to the following algorithm.  
 
1. Negative FDG -PET at baseline, with a positive FDG -PET at 
follow -up is a sign of progression based on a new lesion.  
2. No FDG -PET at baseline and a positive FDG -PET at follow -
up corresponding to a potential new site of disease must have a confi rmation by anatomical assessment (e.g. CT, 
MRI, x -ray) as new site of disease to be considered 
progressive disease.  In such a case, the date of progressive disease will be the date of the initial abnormal FDG -PET.   
e.   Symptomatic deterioration
:  Global  deterioration of health status 
requiring discontinuation of treatment without objective evidence of progression.  Efforts should be made to obtain objective evidence of progression after discontinuation.  
 f.  Assessment inadequate, objective status unknow n
.  
Progression or symptomatic deterioration has not been documented, and one or more target measurable lesions have not been assessed or inconsistent assessment methods were used.  
 g.  Objective status notes:  
 
1.  Non-measurable and non- target measurable disease do not 
affect Objective Status  in determination of CR (must be absent --a patient who otherwise has a CR, but who has non-
measurable or non- target measurable disease present or not 
assessed, will be classified as having a PR). However, non-measurable and non- target lesions are included in 
determination of progression (if new sites of disease develop or if unequivocal progression occurs in the opinion of the treating physician).  
 2.   An objective status of PR or stable cannot follow one of CR.  Stable can follow PR only in the rare case that tumor 
increases too little to qualify as progression, but enough that a previously documented 30% decrease no longer holds.  
 3.    In cases for which initial flare reaction is possible (hypercalcemia, increased bone pain, erythema of skin 
lesions), objective status is not progression unless either symptoms persist beyond 4 weeks or there is additional evidence of progression.   
 4.  Lesions that appear to increase in size due to presence of necrotic tissue will n ot be considered to have progressed.  
 5.   For bone disease documented on bone scan only, increased uptake does not constitute unequivocal progression. However, increase in the soft tissue component of a lesion as measured by CT or MRI would constitute pr ogression.  
 6.   Appearance of new pleural effusions does not constitute unequivocal progression unless cytologically proven of neoplastic origin, since some effusions are a toxicity related 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  42 of 59 
 
to therapy or other medical conditions. Increase in the size of 
an existing effusion does not constitute unequivocal 
progression, since the fluid status of the patient could alter the size of the effusion.  
 7.   If CR determination depends on a lesion for which the status is unclear by the required tests, it is recommended the residual lesion be investigated with biopsy or fine needle aspirate.   
7.3 Best Response 
 
This is calculated from the sequence of objective statuses.  
 
a. CR:  Two or more objective statuses of CR a minimum of four weeks apart documented before progres sion or symptomatic 
deterioration.  
 b.  PR: Two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration, but not qualifying as CR.  
 c.  Unconfirmed CR:  One objective status of CR documented before 
progression or symptomatic deterioration but not qualifying as CR or PR. 
 d.  Unconfirmed PR:  One objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR.  
 
e.  Stable/no response:  At least one objective status of stable/no 
response documented at least 6 weeks after registration and before progression or symptomatic deterioration, but not qualifying as anything else above.  
 f. Increasing disease:  Objective status of pr ogression within 12 
weeks of registration, not qualifying as anything else above.   
 g. Symptomatic deterioration: Objective status of symptomatic deterioration within 12 weeks of registration, not qualifying as anything else above.   
 h. Inadequate assessment, response unknown:  Progression or symptomatic deterioration greater than 12 weeks after registration and no other response category applies.  
 
 
8. Statistical methods and determination of sample size 
8.1 Sample Size Determination  
Overall Survival (OS) at 6 month is the primary  endpoint on this study. OS is defined in 
section 8.2. Dropouts/screen failures defined in section 4.2.2 and those who are lost 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  43 of 59 
 
follow -up prior to 6 months  from starting on trial except death are not evaluable for the 
primary endpoint , and they will be replaced by new patients. The study will test the null 
hypothesis of ≤30% of OS at 6 month against the alternative of ≥50% of OS at 6 month 
(HR = 0. 578 under exponential model ). The sample size was determined, based on the 
Simon’s two -stage minimax design. With one- sided 10% of type I error rate and 90% 
statistical power, a sample of evaluable 39 will be evaluated: 28 in first stage and 
additional 11 in second stage. If 8 or more out of 28 survive 6 months or more, the study goes on the second st age.. REGORAFENIB will be deemed to have good activity if ≥16 
out of 39 patients survive 6 months or more from starting on trial . The continuation of 
accrual may be allowed while the analysis  for early stopping being conducted.  We expect 
to accrue 2 or more patients per month among 6- 7 participating institutions  and will follow 
up patients 6 months or more.   
Dropouts/screen failures defined in section 4.2.2 and those who are lost follow -up prior to 6 
months from starting on trial except death, disease and severe  toxicity are not evaluable for the 
primary endpoint, and they will be replaced by new patients  
 
8.2 Statistical Analysis 
 
Overall survival ( OS) is defined as the time from starting on trial to date of death due to 
any cause and progression- free survival ( PFS) is defined as the duration of time from start 
of treatment to time of progression or death, whichever comes first.  The final analysis will 
be conducted after the follow -time of the last patient exceeds 6 months . The primary  
endpoint  of the study is OS at 6 month. The experimental treatment will be deemed to 
have good activity if ≥16 out of 39 evaluable patients survive 6 months or more.  OS will be 
estimated using the Kaplan- Meier method and the two-sided 95% confidence interval (CI) 
for median OS will be computed using log -log transformation.  
The secondary endpoints in this study include the disease control response (DCR) defined 
as (CR + PR+ SD), toxicity, and PFS. DCR rate will be reported with 95% CI computed by 
the Clopper -Pearson method. The frequency and severity of adverse events and 
tolerability of the regimen will be summarized using descriptive statistics.  PFS with 95% CI 
will be estimated. As exploratory objective, the association between biomarkers and clinical outcomes (DCR rate, OS and PFS) will be examined using multiple logistic regression and the multivariable Cox regression model. A p- value of <0.05 will be 
considered statistically significant. Frequency and severity of adverse events will be 
summarized using descriptive statistics . 
 
9.  Safety Monitor ing  
Safety assessments will consist of monitoring and recording all adverse events and 
serious adverse events, the regular monitoring of hematology and blood chemistry parameters and regular physical examinations. Adverse events will be evaluated continuously throughout the study. Safety and tolerability will be assess ed according to the 
NIH/NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) that is available at:  
http://ev s.nci.nih.gov/ftp1/CTCAE/About.html
 
 
The PMC monitors its assigned ongoing research protocols for: adverse event reporting, 
data and safety monitoring, and internal audit findings.  The PMC, upon review of any 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  44 of 59 
 
agenda item, may approve the study for  continuation, require revisions, suspend or close 
a protocol.  
Investigators of studies, which are designated to be reviewed by the PMC for data and 
safety monitoring, shall provide a statistical report of  the study’s progress and summary of 
adverse events and dev iations  based on the phase of the study and the associated risk of 
the study or  
more often if applicable. The external DSMB (if applicable) shall  forward its report for high-
risk studies designated for external review at  least annually or more often if applicable.  
 
Internal Monitoring Plan  Data will be captured in Oncore, Moffitt’s Clinical Trials Database.  Regulatory documents 
and case report forms will be reviewed routinely according to Moffitt’s Monitoring Policies.  
9.1 Adverse events 
Information about all adverse events, whether volunteered by the subject, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected and recorded and followed as appropriate. An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Medical conditions/diseases present before starting study drug are only considered adverse events if they worsen after starting study drug. Abnormal laboratory values or test results constitute adverse events only if they induce clinical signs or symptoms, are considered clinically significant, or require therapy. The occurrence of adverse events should be sought by non- directive questioning of the patient at each visit 
during the study. Adverse events also may be detected when they are volunteered by the patient during or between visits or through physical examination, laboratory test, or other assessments. As far as possible, each adverse event should be evaluated to determine:  
• The severity grade (grade 1- 4, or mild/moderate/severe)  
• Its relationship to the study drug(s) (suspected/not suspected)  
• Its duration (start and end dates or if continuing at final exam)  
• Action taken (no action taken; study drug dosage adjusted/temporarily interrupted; study drug permanently discontinued due to this adverse event; concomitant medication taken; non- drug therapy given; hospitalization/prolonged 
hospitalization)  
• Whether it constitutes a serious adverse event (SAE)  
  
All adverse events should be treated appropriately. Such treatment may include changes in study drug treatment including possible interruption or discontinuation, starting or stopping concomitant treatments, changes in the frequency or nature of assessments, hospitalization, or any other medically required intervention. Once an adverse event is detected, it should be followed until its resolution, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected 
relationship to the study drug, the interventions required to treat it, and the outcome.   
  Information about common side effects already known about the investigational drug can be found in the Investigator’s Brochure or will be communicated between Investigator Brochure updates in the form of Investigator Notifications. This information will be included in the patient informed consent and should be discussed with the patient during the study as needed.  
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  45 of 59 
 
9.2 Serious adverse events 
  
A serious adverse event is an undesirable sign, symptom or medical condition which:  
• is fatal or life -threatening  
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth defect  
• requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for routine treatment or monitoring of the studied indication 
• is medically significant, i.e., defined as an event that jeopardizes the patient or may require medical or surgical intervention to prevent one of the outcomes listed above 
  Information about all serious adverse events will be collected and recorded. To ensure patient safety, each serious adverse event must be reported to the PI and to Bayer expeditiously.  Moffitt Cancer Center and all participating sites will report SAEs by 
completing an SAE report in ONCORE, the electronic data capture system and a Medwatch Form online at  http://www.fda.gov/medwatch
 The SAE must be reported by 
email ( affiliate.research@moffitt.org) to the MCRN within 2 working days.  
9.3 Reporting of serious adverse events 
The definition of serious adverse events (SAEs) is given in Section 6.2.1.1. 
Each serious adverse event must be followed up until resolution or stabilization, by submission of updated reports to the designated person. An isolated laboratory abnormality that is assigned grade 4, according to CTC definition, is not reportable as an SAE; unless the investigator assesses that the event meets standard ICH criteria for an SAE.  CTC grade 4 baseline laboratory abnormalities that are part of the disease profile should not be reported as an SAE, specifically when they are allowed or not excluded by the protocol inclusion/exclusion criteria.   
 When required, and according to local law and regulations, serious adverse events must be reported to the Ethics Committee and Regulatory Authorities.   
 All serious adverse events should be reported to Bayer within 24 hours.  In the event of 
such an event, the investigator should refer to the Pharmacovigilance section of the contract for reporting procedures.  
 
The Investigator may report serious adverse events (SAEs) as described below.  
 
 
 A MedWatch form available at http://www.fda.gov/medwatch/
  
 
All reports shall be sent electronically to:  
 
Electronic Mailbox:    DrugSafety.GPV.US@bayer.com   
 Facsimile:     (973) 709- 2185  
 Address:    Global Pharmacovigilance - USA  
Mail only:   Bayer HealthCare Pharmaceuticals Inc.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  46 of 59 
 
 P.O. Box 1000  
 Montville, NJ 07045- 1000  
 
Address:     340 Changebridge Road  
FDX or UPS only     Pine Brook, NJ  07058  
 Reports for all Bayer products can also be phoned in via our Clinical Communications Dept:   Phone:    1- 888-765-3203- 2937 
 
9.4 Adverse events of special safety interest  
As with any new chemical entity, there is always potential for unexpected adverse events, 
including hypersensitivity reactions.  
Based on data from phase I/II studies with regorafenib and from current knowledge of the pharmacological properties of other small molecule tyrosine kinase inhibitors in this drug class, as soon as there is reasonable suspicion of any of the following AEs, the investigator should immediately notify the sponsor as outlined in Section 7.6.1.4.  
These events are:  
• Acute renal failure (NCI -CTCAE version 4.0 ≥ grade 3) or severe proteinuria (NCI -
CTCAE version 4.0 ≥ grade 3)  
• Interstitial lung disease 
• Acute cardiac failure 
• Clinically significant bleeding (NCI -CTCA E version 4.0 ≥ grade 3)  
• Stevens -Johnson Syndrome and erythema multiforme 
• Hepatic failure 
 
9.5 Pregnancies 
The investigator must report to Bayer any pregnancy occurring in a study subject, or in his partner, during the subject’s participation in this study.  The report should be submitted within the same timelines as an SAE, although a pregnancy per se is not considered an SAE.   
For a study subject, the outcome of the pregnancy should be followed up carefully, and any abnormal outcome of the mother or the child should be reported.  
For the pregnancy of a study subject’s partner, all efforts should be made to obtain similar information on course and outcome, subject to the partner’s consent.  
For all reports, the forms provided are to be used.  
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  47 of 59 
 
9.6 Further safety  
Progressive disease 
If progressive disease leads to signs and symptoms that meet the criteria for an SAE 
(i.e., hospitalization, disability, death, or important medical event), the signs and symptoms 
should be reported as an SAE and not the underlying progressive disease.  
Death 
If any subject dies during the trial or within 30 days of the end- of-treatment visit, the 
investigator will inform Bayer and record the cause of death in detail (using the SAE Form) 
within 24 hours.  
10.  Premature termination of the study  
• If risk-benefit ratio becomes unacceptable owing to, for example,  
o Safety  findings from this study ( e.g. SAEs)  
o Results of any interim analysis  
o Results of parallel clinical studies  
o Results of parallel animal studies  
(on e.g.  toxicity, teratogenicity, carcinogenicity or reproduction toxicity).  
• If the study conduct ( e.g. recruitment rate; drop- out rate; data quality; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time frame.  
The investigator has the right to close his/her center at any time.  
For any of the above closures, the following applies:  
• Closure s should occur only after consultation between involved parties.  
• All affected institutions ( e.g. IEC(s)/IRB(s); competent authority (ies); study center ; 
head of study center ) must be informed as applicable according to local law.  
• In case of  a partial study closure, ongoing subjects, including those in post study 
follow -up, must be taken care of in an ethical manner.  
Details for individual subject's withdrawal can be found in Section 4.2.1. 
11.   Data recording 
11.1 Institution al Review Board (IRB) Approval and Co nsent 
It is expected that the IRB will have the prope r representation and function  
in accordance wi th federa lly mandated reg ulations.  The I RB should 
approve the conse nt form and protocol. 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  48 of 59 
 
In obt aining  and docum enting  informed conse nt, the investigator should comply 
with the ap plicable regulatory requireme nt(s), and should a dhere to Good Clinical 
Practice (GCP) and to ethical principles tha t have their origin in the Declara tion of 
Helsinki.  
 
Before recruitmen t and en rollment on to this study , the patien t will be give n a full 
explanation of  the study  and will be give n the oppor tunity  to review the conse nt 
form. Each consen t form must inclu de al l the releva nt eleme nts currently required 
by the FD A Reg ulations  and local or state regulations.  O nce this esse ntial 
information has been prov ided to the pat ient and the investi gator is assur ed that 
the patient 
understa nds the  implications of participat ing in the s tudy, the patient will be 
aske d to give conse nt to participa te in the s tudy by sig ning an IRB-a pprove d 
conse nt form. 
 
11.2 Re quired Documen tation 
 
Before the study  can be in itiated at a ny site, the site will be required to provide 
regulatory  docum entat ion to t he Moffitt Clinical Research Network (MCRN) at  Moffitt 
Cancer Center.  
Sites  must  provide a copy  of their informed consent  to the MCR N coordinating  
center for revie w and approval prior to submission of any document s to the site’s IRB. 
Any changes re- quested by the site’s IRB must be provided to the MCRN staff for 
review and approval prior to resubmission to the IRB. 
 
The MCR N Coordinating Center must receiv e the followin g trial specifi c document s 
either by hardcopy , fax, or emai l before a site can be activated for any trial: 
 
1. IRB Approva l Letter that inc ludes the protocol versio n and date 
2. FDA Relate d Form s 1572/1571/310 as appropriate 
3. Signe d Protocol Title Page  
4. IRB Approve d Consent Form  
5. Site Delegatio n of Responsibilit y Log 
6. Signe d  Financ ial Interest Disclo sure Form s (princ ipal and sub investigators)  
7. Updated  Investigator/Per sonnel  document s  (CVs ,  licenses ,  Conflic t  of  
Interest statements , etc) as needed 
8. Updated Laborator y Docu ments (certifications , normal ranges , etc) as 
needed Signed protocol specifi c Task Order  
  
A study initiatio n visit (or teleconference)  will be held prior to the start of any study 
related activit y at the site. Attendanc e is required for:  
• The site PI and appropriat e researc h staff 
• Moffitt  PI and MCR N researc h coordinator is r equired 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  49 of 59 
 
The r equir ement s of the protocol and all associated procedures and processes will be 
reviewed and agreed upon prior to the activatio n of the study . The MCRN 
utilizes the EDC system, OnCore. OnCor e trainin g will be scheduled if 
indicated with the appropriate staff from the site.  
 
11.3 Re gistration Procedures 
All subject s must be registered with the MCR N Coordinati ng Center to be able to 
participate i n a trial. The participating sit e must fax or emai l the completed study 
specifi c eligibility checklis t and registratio n forms , supporting document s and signe d 
informed consent to the Coordinating Center . Unsigne d or incom plete forms will be 
returned to t he site. Once document s are received, the MCR N Re searc h Co ordinator 
will revie w them to confirm eligibility and to complet e the regis tration process . If 
eligib ility can not be confirmed, the researc h coordinator will query  the site for 
clarification  or additional docum ents as needed. Subject s failing to meet all study 
eligib ility requirem ents will not be registered and will be unable to participate in the 
trial. 
 
Upon 
completio n of registration, the MCR N Researc h Coordi nator will provide the 
participat ing site with the study sequence number and randomi zation information if 
indicated. Within 24- 48 hours after registration, It is the site’s responsibility to:  
• Enter the demographic and on -study patient information into the OnCor e 
databas e 
• Order  investigational  agent(s)  if indicated per protocol  
  
It is the responsibi lity of the participating Investiga tor or designee to inform the 
subjec t of the researc h treatment plan and to conduc t the study in compliance 
with the protocol as agreed upon with Moffitt  Cancer Center  and approved by the 
site’s IRB. 
To register a patient send the completed signed eligibility checklist along with 
supporting documentation to the MCRN via email at affiliate.research@moffitt.org  or 
via fax at 813- 745-5666, Monday through Friday between 8:00AM and 
5:00PM(EST).  
 
11.4 D ata Managemen t and Monitoring/Auditing 
All participating sites are requi red to enter and submi t data through the Oncolog y 
Research Management  software (OnCore)  electroni c data syste m.Data  will be 
monitored for subjec t eligibilit y and protocol compliance, as well as for accuracy and 
completeness,  
 
To obtai n acces s to OnCore, the site researc h staff must complete an OnCor e 
Access Reques t Form and a M offitt Information System s Confi dentiality  Agreement  
and submit  both to the Coordinating  Center.  Once the completed forms are received, 
the site coordinator will receiv e a VPN acces s key, logon/ password, and information on 
how to access OnCore using the VPN. The MCR N Coordinating Center will provide 
OnCor e training  to the site once initial acces s is granted and on an ongoing basis as 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  50 of 59 
 
needed. Written  instructio ns  will be provided electronicall y for each site to download 
prior to the initial trainin g with updates sent  as appropriate.   
 
11.5 Adherence to the Protocol 
Exce pt for an emergency situ ation in which proper ca re for the pr otection, safety, and well-
being of the study  patient requires alte rnative treatmen t, the study  shall be conducted 
exactly  as describe d in the approve d protocol 
 
 
11.6 Em ergency Modific ations 
Moffitt Cancer Center and Affiliate investigators may impleme nt a devia tion from, 
or a change of , the protoco l to eliminate an i mmedia te haza rd(s) to  trial subjects 
without prior H. Lee Moffitt Cancer Center or  their respective institution’s 
approval/favorable opinion.  
 
 
For Institutions  Relying on Moffitt's  IRB: 
For any such emergency modi fication implemented , a Moffitt  IRB mod ification 
form mu st be com plete d by Moffitt Research Personne l within five (5) business 
days of making the change. 
 
 
For Institutions  Relying o n Their Ow n IRB: 
For Affiliate investigators relying on the ir own institution’s  IRB, as soon a s possible 
after the modi fication has b een made , the im plemented deviat ion or  change an d 
the reasons  for it should be submi tted to: To Moffitt  Principa l Investi gator for 
agreeme nt and t he Affiliate institution’s IRB for review a nd approval. (Once  IRB‟s 
response is receive d, this  should be f orwarded to t he  MCRN).  
 
11.7 R ecord Retenti on 
 
Study docum entat ion includes al l eCRFs, d ata correction forms or queries, 
source docume nts, Sponsor-Inv estigator correspondence , monitor ing 
logs/letters, a nd regulatory docum ents (e.g., pro tocol and ame ndments, IRB 
correspondence an d approva l, signe d patient conse nt forms). 
 
Source 
docum ents inclu de all recordings of observat ions or nota tions  of clinical 
activities a nd all reports and records  necessa ry for the eva luation and 
reconstruction of  the clinica l research study. 
 
Gove rnme nt agency reg ulations  and di rectives re quire that all study  
docum entation perta ining  to the co nduct of a clin ical trial must be reta ined by the 
study  investi gator. In the case of a study  with a drug seeking  regulatory approva l 
and market ing, these docume nts shal l be retai ned for at least tw o years after the 
last ap prova l of marke ting application in an International Con ference o n 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  51 of 59 
 
Harm onization ( ICH) region.  In all oth er cases, study  docum ents should be ke pt 
on file until three years after the complet ion and final study re port of this 
investigational study. 
 
11.8 Ob ligations of Investigators 
The Principa l Investi gator is responsib le for the conduct of  the clinical trial at the 
site in accor dance w ith Title 21 of the Code of Federa l Regulations  and/or  the 
Declarat ion of  Helsinki.  The Princ ipal Investi gator is responsib le for persona lly 
overseeing  the tr eatme nt of all study  patients.  The Princ ipal Investi gator must 
assure that a ll study site personne l, including  sub- investigators and other stu dy 
staff members, adhere to the study  protocol and all FDA/GCP/N CI regulations 
and guidelines rega rding 
clinica l trials both du ring and after study  compl etion. 
 
The Principa l Investi gator at each institution or site w ill be responsib le for 
assur ing that al l the requ ired data w ill be collecte d and entere d into the e CRFs. 
Periodically , monit oring visits  will be conducte d and the Pr incipal Investi gator wi ll 
provide access to hi s/her original records  to per mit verificati on of  prope r entry of 
data. At the complet ion of  the study , all eCRFs w ill be reviewed by the Principa l 
Investi gator and will require his/her final signature to verify the accur acy of the 
data. 
 
12. Ethical and legal aspects 
12.1 Ethical and legal conduct of the study  
 
The procedures set out in this protocol, pertaining to the conduct, evaluation, and 
documentation of this study, are designed to ensure that the investigator abide by Good Clinical Practice (GCP) guidelines and under the guiding principles detailed in the Declaration of Helsinki.  The study will also be carried out in keeping with applicable local law(s) and regulation(s).  
Documented approval from appropriate IEC(s)/IRBs will be obtained for all participating centers before start of the study, according to GCP, local laws, regulations and organizations.  When necessary, an extension, amendment or renewal of the EC/IRB approval must be obtained and also forwarded to Bayer.  
Strict adherence to all specifications laid down in this pr
 otocol is required for all aspects of 
study conduct; the investigator may not modify or alter the procedures described in this protocol.   
Modifications to the study protocol will not be implemented by the investigator without discussion and agreement by Bayer.  However, the investigator may implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to the trial subjects without prior IEC/IRB/Bayer approval/favorable opinion.  As soon as possible, the implemented deviation or change, the reasons for it and if appropriate the proposed 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  52 of 59 
 
protocol amendment should be submitted to the IEC/IRB/head of medical institution.  Any 
deviations from the protocol must be explained and documented by the investigator.  
The Principal Investigator is responsible for the conduct of the clinical trial at the site in accordance with Title 21 of the Code of Federal Regulations and/or the Declaration of Helsinki.  The Principal Investigator is responsible for personally overseeing the treatment of all study patients.  The Principal Investigator must assure that all study site personnel, 
including sub- investigators and other study staff members, adhere to the study protocol 
and all FDA/GCP/NCI regulations and guidelines regarding clinical trials both during and after study completion.  
The Principal Investigator at each institution or site will be responsible for assuring that all the required data will be collected and properly documented.  
12.2 Subject information and consent  
Each subject / legal representative or proxy consenter will have ample time and opportunity to ask questions and will be informed about the right to withdraw from the study at any time without any disadvantage and without having to provide reasons for this decision.  
Only if the subject / legal representative or proxy consenter voluntarily agrees to sign the informed consent form and has done so, may he/she enter the study.  Additionally, the investigator and other information provider (if any) will personally sign and date the form.  The subject / legal representative or proxy consenter will receive a copy of the signed and dated form.  
The signed informed consent statement is to remain in the investigator site file or, if locally required, in the patient’s note/file of the medical inst itution.  
In the event that informed consent is obtained on the date that baseline study procedures are performed, the study record or subject’s clinical record must clearly show that informed consent was obtained prior to these procedures.  
1. If the patient is not capable of providing a signature, a verbal statement of consent can also be given in the presence of an impartial witness (independent of Bayer and the investigator).  This is to be documented by a signature from the informing physician as well as  by a signature from the witness.  
2. For minors or adults under legal protection, consent shall be given by the legal guardian(s).  The consent of a minor or adult under legal protection shall also be requested where such a person is able to express his/her own will.  His/her refusal or the withdrawal of his/her consent may not be disregarded.  
3. In emergency situations, when prior consent of the patient is not possible, the consent of the patient’s legal representative(s) or proxy consenter, if present, should be requested.  The patient should be informed about the study as soon as possible and his/her consent to continue the study should be requested.  
The informed consent form and any other written information provided to subjects / legal representatives or proxy consenters will be revised whenever important new information becomes available that may be relevant to the subject’s consent, or there is an 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  53 of 59 
 
amendment to the protocol that necessitates a change to the content of the subject 
information and / or the written informed consent form.  The investigator will inform the subject / legal representative or proxy consenter of changes in a timely manner and will ask the subject to confirm his/her participation in the study by signing the revised informed consent form.  Any revised written informed consent form and written information must receive the IEC/IRB`s approval / favorable opinion in advance of use.  
12.3 Publication policy  
Bayer recognizes the right of the investigator to publish results upon completion of the study.  However, the investigator must send a draft manuscript of the publication or abstract to Bayer at least thirty days in advance of submission in order to obtain approval prior to submission of the final version for publication or congress presentation.  This will be reviewed promptly and approval will not be withheld unreasonably.  In case of a difference of opinion between Bayer and the investigator(s), the contents of the publication will be discussed in order to find a solution which satisfies both parties. All relevant aspects regarding data reporting and publication will be part of the contract between Bayer and the investigator/institution 
The Principal Investigator should ensure that the information regarding the study be 
publicly available on the internet at www.clinicaltrials.gov
. 
12.4 Confidentiality  
All records identifying the subject will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available.  
Should direct access to medical records require a waiver or authorization separate from the subject’s statement of informed consent, it is the responsibility of the Investigator to obtain such permission in writing from the appropriate individual.  
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  54 of 59 
 
 
13. Correlative studies  
13.1 Re quired Particip ation 
Regorafenib is  a  multi-kinase inhibitor that is believe d to block tumor growth throug h effects 
on both t umor cells and the ang iogenic compartme nt.  At present, th ere is no way to predict 
which patie nts will benefit from this compo und.  Bi omarke r studi es wil l be perf ormed to 
investigate the mecha nisms by w hich regorafenib works in an attemp t to identify markers 
predictive of drug benefit in patien ts with advanced biliary tumors . In the curr ent study, b oth 
gene tic and non-genetic bi omarker analyses a re planne d on blood  sp ecimens.  Utmost care 
will be taken to pr otect p atient identity during biom arker analyses. Collect ion, pr ocessin g, 
handlin g, and shippi ng of biomarker sam ples wi ll be p erformed as describe d in the la boratory 
manual 
 
13.2 
Details on Potenti al Biomarker Studies by Specimen 
 
Plasma samples: The Duke Molecular Reference Laboratory at Duke University Medical 
Center is one of several core facilities for CALGB. It acts as a molecular profiling laboratory 
for blood- based biomarkers of targeted therapies, particularly targeted anti -angiogenic 
agents.  Drs. Andrew Nixon and Herbert Hurwitz serve as co- directors of the facility and 
direct the overall research of the laboratory.  The laboratory has qual ity control procedures 
in place to address many of the issues involved in clinical trials research including sample quantity, sample integrity, and sample heterogeneity. The services provided align with our programmatic focus around the interrogation of bl ood and urine samples by either multiplex 
or standard ELISA technologies.  Each study utilizes unique combinations of cancer therapeutics, affecting multiple signaling pathways.  The optimal design for this study addresses the specific drug targets of the study as well as attempting to capture the relevant 
co- and counter -regulated proteins.  Based on our experience, we have chosen important 
pathway components, identified the appropriate assay, built multiplex panels, and established QA/QC parameters regarding these assays.  
 
In the past, the gold standard for detection of growth factors and cytokines in blood was the 
use of ELISAs; however, multiplex technology offers an attractive alternative approach for cytokine and growth factor analysis. This novel technology allows for the measurement of multiple analytes simultaneously from a single sample.  The advantages of multiplex technology compared to traditional ELISA assays are conservation of patient sample, increased sensitivity, and significant savings in cost, time and labor.  Furthermore, all plate designs are validated in order to 1) limit cross -reactivity of the antibodies 2) optimize 
sensitivity and specificity and 3) maximize the linearity of the assay’s dynamic range.  
 
Several systems exist, the plate- based platforms being the Meso Scale Discovery (MSD) 
multiplex system and the SearchLight system, produced by Aushon Biosystems (formerly of 
ThermoFisher Scientific). The assay design in both cases is similar to a sandwich ELISA, 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  55 of 59 
 
except multiple capture antibodies are pre- spotted into individual wells of a 96- well plate. 
Samples or standards are added which bind to the specific capture antibodies and are 
detected using various outputs.  Over the past 2 years, we have optimized the design of customized multiplex ELISA plates via extensive collaborations with the SearchLight.  We have devoted considerable effort to this and have developed an appropriately designed panel for the simultaneous evaluation of up to 40 regulators of tumor and normal angiogenesis.  Table 1 lists the analytes that can be evaluated. Modifications to this list may occur during patient accrual, but the programmatic theme related to angiogenesis will remain constant.  Standard ELISA assays are also included to evaluate soluble TGF RIII 
and IGF- 1 as additional blood markers.   
 All multiplex plate designs have been validated in order to limit cross -reactivity of the 
antibodies, optimized for sensitivity and specificity, and maximize the linearity of the assay’s dynamic range. The CVs of the multiplex arrays are approximately 15- 20%, depending on 
the particular assay. Any study samples that fall outside the linear portion of the standard curve are retested. Samples that read below the limit of detection are retested, if possible.  
Samples that read above the linear portion of the standard curve are serially diluted and retested to obtain accurate measurements.  Any analyte that does not meet the aforementioned criteria will result in the sample being re- evaluated. Analytes of inter est that 
are not available in our multiplex plates can be evaluated using commercial ELISA kits or “home- brew” ELISAs.  
  
Table 1.  Plasma- based marker identification 
Soluble 
Angiogenic 
Factors* Matrix-Derived 
Angiogenic 
Factors Markers of 
Coagulation 
Markers of 
Vascular 
Activation and 
Inflammation  
bFGF  MMP2  Tissue Factor  Gro- 
HGF  MMP9  PAI-1 Active  IL-6 
PlGF  TGF1 PAI-1 Total  IL-8 
VEGF -A TGF2 CRP  P-selectin  
VEGF -C Osteopontin  D-dimer  E-selectin  
VEGF -D TSP1  Von Willebrand  
Factor  SDF-1 
ANG -2 TSP2  ICAM -1 
PDGF -AA BMP9   VCAM -1 
PDGF -BB sEndoglin   MCP -1 
IGFBP1  PEDF   E-cadherin  
IGFBP2     
IGFBP3     
sVEGFR1     
sVEGFR2     
*Standard ELISA assays will also be included to evaluate soluble TGFbRIII, and 
IGF-1 as additional blood markers.  
 
Lastly, all samples have appropriate chain- of-custody documentation to ensure compliance 
with FDA and IRB regulations.  We have systems in place detailing the location, transfer, 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  56 of 59 
 
and use of any and all human research subject samples. Any discrepancies or omissions in 
flow sheets and/or sample labels are resolved upon receipt of the sample i n the lab.  All 
sample and data handling procedures will be fully compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). We have sample handling protocols that provide step- by-step details for sample isolation, sample handling, and sample 
receipt/shipment.  Samples are housed in ultra low temperature freezers ( -80°C).  The 
freezers are monitored daily and are equipped with an alarm system designed to alert laboratory personnel upon freezer malfunction. Additionally, we have implemented a secondary, independent alarm system on all ultra low freezers currently used to store all patient samples.  Use of these redundant systems greatly reduces the chance of freezer failure, which could potentially result in the loss of irreplaceable samples from hundreds of clinical trial patients.  
 
  
13.3 Special Instructions 
 
For plasma samples
: 
 
1. Draw  1 x10ml s EDTA t ube 
2. Invert tubes 10 times to mix blood 
3. Centrifuge at 4°C at 2500 x g for 15 minutes (or in accordance with centrifuge manufacturer’s 
instructions)  
4. Remove plasma from each tube and transfer equally into two separate clean 15ml polypropylene tubes  
5. Repeat centrifuge at 4°C at 2500 x g for 15 minutes (or in accordance with centrifuge manufacturer’s instructions)  
6. Aliquot approximately 1.0ml of  plasma from each tube into each 2.0ml cryovial.  For the EDTA, 
aliquot into pink capped cryovial.  Total of 3 pink capped cryovials needed for EDTA plasma.  For the sodium citrate, aliquot into blue capped cryovial.  Total of 2 blue capped cryovials needed for sodium citrate plasma.  
7. Label and freeze at -80°C* (see labeling instructions below)  
 
 
13.4   Shipping 
• All biomarker samples (whole blood, plasma, serum and urine) must be 
shipped on dry ice by overnight delivery Monday through Thursday (no holidays) to the 
following address:  
 
Attention:  Phase I Biomarker Laboratory  
     ATTN:  Andrew Nixon, PhD  
Duke University Medical Center  
395 MSRB, Research Drive 
Durham, NC 27710 
 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  57 of 59 
 
14. Reference list  
 
[1] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 
2010;60:277- 300. 
[2] Shaib YH, Davila JA, McGlynn K, El -Serag HB. Rising incidence of intrahepatic 
cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472- 7. 
[3] Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507- 17; discussion 17- 9. 
[4] Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-81. 
[5] Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. Journal of hepato- biliary -
pancreatic sciences. 2012;19:326- 36. 
[6] Bergers G, Benjamin LE. Tumorigenesis  and the angiogenic switch. Nat Rev Cancer. 
2003;3:401- 10. 
[7] Mobius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mossner J, et al. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Ejso. 2007;33:1025- 9. 
[8] Park BK, Paik YH, Park JY, Park KH, Bang SM, Park SW, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor -C in intrahepatic 
cholangiocarcinoma. American Journal of Clinical Oncology -Cancer  Clinical Trials. 
2006;29:138- 42. 
[9] Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 1999;19:2257- 60. 
[10] Aishima S, Taguchi K, Sugimachi K, Asayama Y, Nishi H, Shimada M, et al. The role of thymidine phosphorylase and thrombospondin- 1 in angiogenesis and progression of 
intrahepatic cholangiocarcinoma. International Journal of Surgical Pathology. 2002;10:47-
56. 
[11] Guedj N, Zhan Q, Perigny M, Rautou PE, Degos F, Belghiti J, et al. Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. Journal of Hepatology. 2009;51:93- 101. 
[12] Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone A, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary -tract 
cancers and correlation of changes in 18- fluorodeoxyglucose PET with clinical outcome: a 
phase 2 study. Lancet Oncology. 2010;11:48- 54. 
[13] Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28:3491- 7. 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  58 of 59 
 
[14] Olesen RK  RR, Ladekarl M, Pfeiffer P,  Soerensen M, Lassen U. . A phase II study of 
erlotinib and bevacizumab in patients with advanced upper gastrointestinal (GI) cancers refractory to chemotherapy. Gastrointestinal Cancers Symposium 2009:(Abstract) 170.  
[15] El -Khoueiry AB, Rankin CJ, Ben- Josef E, Lenz HJ, Gold PJ, Hamilton RD, et al. SWOG 
0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drug. 2012;30:1646- 51. 
[16] Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. British Journal of Cancer. 2010;102:68- 72. 
[17] O'Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer. 2004;90:283- 8. 
[18] Herrera R, Sebolt -Leopold JS. Unraveling the complexities of the Raf/MAP kinase 
pathway for pharmacological intervention (vol 8, pg S27, 2002). Trends Mol Med. 2002;8:243-. 
[19] Ahn NG, Nahreini TS, Tolwinski NS, Resing KA. Pharmacologic inhibitors of MKK1 and 
MKK2. Methods Enzymol. 2001;332:417- 31. 
[20] Horiuchi H, Kawamata H, Fujimori T, Kuroda Y. A MEK inhibitor (U0126) prolongs survival in nude mice bearing human gallbladder cancer cells with K -ras mutation: analysis 
in a novel orthotopic inoculation model. Int J Oncol. 2003;23:957- 63. 
[21] Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52:706- 12. 
[22] Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, et al. K -ras mutation, 
p53 overexpression, and microsatellite instability in biliary tract cancers: a population- based 
study in China. Clin Cancer Res. 2002;8:3156- 63. 
[23] Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K -ras mutations in intrahepatic 
cholangiocarcinoma of the liver. Gut. 2000;47:721- 7. 
[24] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949- 54. 
[25] Reeves ME, DeMatteo RP. Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol. 2000;19:84- 93. 
[26] Goldenberg D, Rosenbaum E, Argani P, Wistuba II, Sidransky D, Thuluvath PJ, et al. The V599E BRAF mutation is uncommon in biliary tract cancers. Modern Pathology. 2004;17:1386- 91. 
[27] Hori H, Ajiki T, Mita Y, Horiuchi H, Hirata K, Matsum oto T, et al. Frequent activation of 
mitogen- activated protein kinase relative to Akt in extrahepatic biliary tract cancer. J 
Gastroenterol. 2007;42:567- 72. 
[28] Jimeno A, Rubio- Viqueira B, Amador ML, Grunwald V, Maitra A, Iacobuzio- Donahue C, 
et al. Dual mitogen- activated protein kinase and epidermal growth factor receptor inhibition 
in biliary and pancreatic cancer. Mol Cancer Ther. 2007;6:1079- 88. 
   
27  January  2015 Version:  REGORAFENIB ISS Template  Page:  59 of 59 
 
[29] Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. Targeting 
PDGFR- beta in Cholangiocarcinoma. Liver international : official journal of the International 
Association for the Study of the Liver. 2012;32:400- 9. 
[30] Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53- 62. 
[31] Wilhelm SM, Dumas  J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib 
(BAY 73 -4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic 
receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245- 55. 
[32] Gr othey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib 
monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo- controlled, phase 3 trial. Lancet. 
2013;381:303- 12. 
 
 